<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-5641-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SEROQUEL 25 MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        QUETIAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        32.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AstraZeneca" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AstraZeneca
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Luye Pharma Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AH04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Seroquel contains a substance called quetiapine. This belongs to a group of medicines called antipsychotics.<br />Seroquel can be used to treat several illnesses, such as:</p><ul><li>Bipolar depression: where you feel sad. You may find that you feel depressed, feel guilty, lack energy, lose your appetite or can&rsquo; t sleep.</li><li>Mania: where you may feel very excited, elated, agitated, enthusiastic or hyperactive or have poor judgment including being aggressive or disruptive.</li><li>Schizophrenia: where you may hear or feel things that are not there, believe things that are not true or feel unusually suspicious, anxious, confused, guilty, tense or depressed.</li></ul><p>Your doctor may continue to prescribe Seroquel even when you are feeling better.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Seroquel:</strong></p><ul><li>&nbsp;if you are allergic to quetiapine or any of the other ingredients of this medicine (listed in section 6).</li><li>&nbsp;if you are taking any of the following medicines:</li></ul><p>- Some medicines for HIV<br />- Azole medicines (for fungal infections)<br />- Erythromycin or clarithromycin (for infections)<br />- Nefazodone (for depression).</p><p>If you are not sure, talk to your doctor or pharmacist before taking Seroquel.</p><p><strong>Warnings and Precautions</strong></p><p>Talk to your doctor or pharmacist before taking Seroquel:</p><ul><li>&nbsp;if you, or someone in your family, have or have had any heart problems, for example heart rhythm problems, weakening of the heart muscle or inflammation of the heart or if you are taking any medicines that may have an impact on the way your heart beats.</li><li>&nbsp;if you have low blood pressure.</li><li>&nbsp;if you have had a stroke, especially if you are elderly.</li><li>&nbsp;if you have problems with your liver.</li><li>&nbsp;if you have ever had a fit (seizure).</li><li>&nbsp;if you have diabetes or have a risk of getting diabetes. If you do, your doctor may check your blood sugar levels while you are taking Seroquel.</li><li>&nbsp;if you know that you have had low levels of white blood cells in the past (which may or may not have been caused by other medicines).</li><li>&nbsp;if you are an elderly person with dementia (loss of brain function). If you are, Seroquel should not be taken because the group of medicines that Seroquel belongs to may increase the risk of stroke, or in some cases the risk of death, in elderly people with dementia.</li><li>if you are an elderly person with Parkinson&rsquo;s disease/parkinsonism.</li><li>&nbsp;if you or someone else in your family has a history of blood clots, as medicines like these have been associated with formation of blood clots.</li><li>&nbsp;if you have or have had a condition where you stop breathing for short periods during your normal nightly sleep (called &ldquo; sleep apnoea&rdquo; ) and are taking medicines that slow down the normal activity of the brain (&ldquo; depressants&rdquo; ).</li><li>&nbsp;if you have or have had a condition where you can&rsquo; t completely empty your bladder (urinary retention), have an enlarged prostate, a blockage in your intestines, or increased pressure inside your eye. These conditions are sometimes caused by medicines (called &ldquo; anti-cholinergics&rdquo; ) that affect the way nerve cells function in order to treat certain medical conditions.</li><li>&nbsp;if you have a history of alcohol or drug abuse.</li></ul><p><u>Tell your doctor immediately if you experience any of the following after taking Seroquel:</u></p><ul><li>&nbsp;A combination of fever, severe muscle stiffness, sweating or a lowered level of consciousness (a disorder called &ldquo; neuroleptic malignant syndrome&rdquo; ). Immediate medical treatment may be needed.</li><li>&nbsp;Uncontrollable movements, mainly of your face or tongue.</li><li>&nbsp;Dizziness or a severe sense of feeling sleepy. This could increase the risk of accidental injury (fall) in elderly patients.</li><li>&nbsp;Fits (seizures).</li><li>&nbsp;A long-lasting and painful erection (Priapism).</li></ul><p>These conditions can be caused by this type of medicine.</p><p><u>Tell your doctor as soon as possible if you have:</u></p><ul><li>&nbsp;A fever, flu-like symptoms, sore throat, or any other infection, as this could be a result of a very low white blood cell count, which may require Seroquel to be stopped and/or treatment to be given.</li><li>&nbsp;Constipation along with persistent abdominal pain, or constipation which has not responded to treatment, as this may lead to a more serious blockage of the bowel.</li><li>&nbsp;Thoughts of suicide and worsening of your depression</li></ul><p>If you are depressed you may sometimes have thoughts of harming or killing yourself. These may be increased when first starting treatment, since these medicines all take time to work, usually<br />about two weeks but sometimes longer. These thoughts may also be increased if you suddenly stop taking your medication. You may be more likely to think like this if you are a young adult. Information from clinical trials has shown an increased risk of suicidal thoughts and/or suicidal behaviour in young adults aged less than 25 years with depression.</p><p>If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away. You may find it helpful to tell a relative or close friend that you are depressed, and ask them to read this leaflet. You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.</p><p>Severe cutaneous adverse reactions (SCARs)<br />Severe cutaneous adverse reactions (SCARs) which can be life threatening or fatal have been reported very rarely with treatment of this medicine. These are commonly manifested by:<br />&bull; Stevens-Johnson syndrome (SJS), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals.<br />&bull; Toxic Epidermal Necrolysis (TEN), a more severe form causing extensive peeling of the skin<br />&bull; Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) consists of flu-like symptoms with a rash, fever, swollen glands, and abnormal blood test results (including increased white blood cells (eosinophilia) and liver enzymes).<br />Stop using Seroquel if you develop these symptoms and contact your doctor or seek medical attention immediately.</p><p><strong>Weight gain</strong><br />Weight gain has been seen in patients taking Seroquel. You and your doctor should check your weight regularly.<br /><strong>Children and adolescents</strong><br />Seroquel is not for use in children and adolescents below 18 years of age.</p><p><strong>Other medicines and Seroquel</strong><br />Tell your doctor if you are taking, have recently taken or might take any other medicines.<br />Do not take Seroquel if you are taking any of the following medicines:</p><ul><li>&nbsp;Some medicines for HIV.</li><li>&nbsp;Azole medicines (for fungal infections).</li><li>&nbsp;Erythromycin or clarithromycin (for infections).&nbsp;</li><li>&nbsp;Nefazodone (for depression).</li></ul><p>Tell your doctor if you are taking any of the following medicines:</p><ul><li>&nbsp;Epilepsy medicines (like phenytoin or carbamazepine).</li><li>&nbsp;High blood pressure medicines.</li><li>&nbsp;Barbiturates (for difficulty sleeping).</li><li>&nbsp;Thioridazine or Lithium (other anti-psychotic medicines).</li><li>&nbsp;Medicines that have an impact on the way your heart beats, for example, drugs that can cause an imbalance in electrolytes (low levels of potassium or magnesium) such as diuretics (water pills) or certain antibiotics (drugs to treat infections).</li><li>&nbsp;Medicines that can cause constipation.</li><li>&nbsp;Medicines (called &ldquo; anti-cholinergics&rdquo; ) that affect the way nerve cells function in order to treat certain medical conditions.</li></ul><p>Before you stop taking any of your medicines, please talk to your doctor first.</p><p><strong>Seroquel with food, drink and alcohol</strong></p><ul><li>&nbsp;Seroquel can be taken with or without food.</li><li>&nbsp;Be careful how much alcohol you drink. This is because the combined effect of Seroquel and alcohol can make you sleepy.</li><li>&nbsp;Do not drink grapefruit juice while you are taking Seroquel. It can affect the way the medicine works.</li></ul><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby ask your doctor for advice before taking this medicine. You should not take Seroquel during pregnancy unless this has been discussed with your doctor. Seroquel should not be taken if you are breast-feeding.</p><p><br />The following symptoms which can represent withdrawal may occur in newborn babies of mothers that have used Seroquel in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.</p><p><strong>Driving and using machines</strong><br />Your tablets may make you feel sleepy. Do not drive or use any tools or machines until you know how the tablets affect you.</p><p><strong>Seroquel contains lactose</strong></p><p>Seroquel contains lactose which is a type of sugar. If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.</p><p><strong>Seroquel contains sodium</strong><br />This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p><strong>Effect on Urine Drug Screens</strong><br />If you are having a urine drug screen, taking Seroquel may cause positive results for methadone or certain drugs for depression called tricyclic antidepressants (TCAs) when some test methods are used, even though you may not be taking methadone or TCAs. If this happens, a more specific test can be performed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if<br />you are not sure. Your doctor will decide on your starting dose. The maintenance dose (daily dose) will<br />depend on your illness and needs but will usually be between 150 mg and 800 mg.</p><ul><li>&nbsp;You will take your tablets once a day, at bedtime or twice a day, depending on your illness.</li><li>&nbsp;Swallow your tablets whole with a drink of water.</li><li>&nbsp;You can take your tablets with or without food.</li><li>&nbsp;Do not drink grapefruit juice while you are taking Seroquel. It can affect the way the medicine works.</li><li>&nbsp;Do not stop taking your tablets even if you feel better, unless your doctor tells you.</li></ul><p><strong>Liver problems</strong><br />If you have liver problems your doctor may change your dose.<br /><strong>Elderly people</strong><br />If you are elderly your doctor may change your dose.<br /><strong>Use in children and adolescents</strong><br />Seroquel should not be used by children and adolescents aged under 18 years.<br /><strong>If you take more Seroquel than you should</strong><br />If you take more Seroquel than prescribed by your doctor, you may feel sleepy, feel dizzy and experience abnormal heart beats. Contact your doctor or nearest hospital straight away. Keep the Seroquel tablets with you.<br /><strong>If you forget to take Seroquel</strong><br />If you forget to take a dose, take it as soon as you remember. If it is almost time to take the next dose, wait until then. Do not take a double dose to make up for a forgotten tablet.</p><p><strong>If you stop taking Seroquel</strong><br />If you suddenly stop taking Seroquel, you may be unable to sleep (insomnia), or you may feel sick (nausea), or you may experience headache, diarrhoea, being sick (vomiting), dizziness or irritability.<br />Your doctor may suggest you reduce the dose gradually before stopping treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br /><strong>Very common: may affect more than 1 in 10 people</strong></p><ul><li>&nbsp;Dizziness (may lead to falls), headache, dry mouth.</li><li>&nbsp;Feeling sleepy (this may go away with time, as you keep taking Seroquel) (may lead to falls).</li><li>&nbsp;Discontinuation symptoms (symptoms which occur when you stop taking Seroquel) include notbeing able to sleep (insomnia), feeling sick (nausea), headache, diarrhoea, being sick (vomiting), dizziness and irritability. Gradual withdrawal over a period of at least 1 to 2 weeks is advisable.</li><li>&nbsp;Putting on weight.</li><li>&nbsp;Abnormal muscle movements. These include difficulty starting muscle movements, shaking, feeling restless or muscle stiffness without pain.</li><li>&nbsp;Changes in the amount of certain fats (triglycerides and total cholesterol).</li></ul><p><strong>Common: may affect up to 1 in 10 people</strong></p><ul><li>&nbsp;Rapid heartbeat.</li><li>&nbsp;Feeling like your heart is pounding, racing or has skipped beats.</li><li>&nbsp;Constipation, upset stomach (indigestion).</li><li>&nbsp;Feeling weak.</li><li>&nbsp;Swelling of arms or legs.</li><li>&nbsp;Low blood pressure when standing up. This may make you feel dizzy or faint (may lead to falls).</li><li>&nbsp;Increased levels of sugar in the blood.</li><li>&nbsp;Blurred vision.</li><li>&nbsp;Abnormal dreams and nightmares.</li><li>&nbsp;Feeling more hungry.</li><li>&nbsp;Feeling irritated.</li><li>&nbsp;Disturbance in speech and language.</li><li>&nbsp;Thoughts of suicide and worsening of your depression.</li><li>&nbsp;Shortness of breath.</li><li>&nbsp;Vomiting (mainly in the elderly).</li><li>&nbsp;Fever.</li><li>&nbsp;Changes in the amount of thyroid hormones in your blood.</li><li>&nbsp;Decreases in the number of certain types of blood cells.</li><li>&nbsp;Increases in the amount of liver enzymes measured in the blood.</li><li>&nbsp;Increases in the amount of the hormone prolactin in the blood. Increases in the hormone prolactin</li></ul><p>could in rare cases lead to the following:<br />o Men and women to have swelling breasts and unexpectedly produce breast milk.<br />o Women to have no monthly periods or irregular periods.</p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><ul><li>&nbsp;Fits or seizures.</li><li>&nbsp;Allergic reactions that may include raised lumps (weals), swelling of the skin and swelling around the mouth.</li><li>&nbsp;Unpleasant sensations in the legs (also called restless legs syndrome).</li><li>&nbsp;Difficulty swallowing.</li><li>&nbsp;Uncontrollable movements, mainly of your face and tongue.</li><li>&nbsp;Sexual dysfunction.</li><li>&nbsp;Diabetes.</li><li>&nbsp;Change in electrical activity of the heart seen on ECG (QT prolongation).</li><li>&nbsp;A slower than normal heart rate which may occur when starting treatment and which may be associated with low blood pressure and fainting.</li><li>&nbsp;Difficulty in passing urine.</li><li>&nbsp;Fainting (may lead to falls).</li><li>&nbsp;Stuffy nose.</li><li>&nbsp;Decrease in the amount of red blood cells.</li><li>&nbsp;Decrease in the amount of sodium in the blood.</li><li>&nbsp;Worsening of pre-existing diabetes.</li></ul><p><strong>Rare: may affect up to 1 in 1,000 people</strong></p><ul><li>&nbsp;A combination of high temperature (fever), sweating, stiff muscles, feeling very drowsy or faint (a disorder called &ldquo; neuroleptic malignant syndrome&rdquo; ).</li><li>&nbsp;Yellowing of the skin and eyes (jaundice).</li><li>&nbsp;Inflammation of the liver (hepatitis).</li><li>&nbsp;A long-lasting and painful erection (priapism).</li><li>&nbsp;Swelling of breasts and unexpected production of breast milk (galactorrhoea).</li><li>&nbsp;Menstrual disorder.</li><li>&nbsp;Blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. If you notice any of these symptoms seek medical advice immediately.</li><li>Walking, talking, eating or other activities while you are asleep.</li><li>&nbsp;Body temperature decreased (hypothermia).</li><li>&nbsp;Inflammation of the pancreas.</li><li>&nbsp;A condition (called &ldquo; metabolic syndrome&rdquo; ) where you have a combination of 3 or more of the following: an increase in fat around your abdomen, a decrease in &ldquo; good cholesterol&rdquo; (HDL-C), an increase in a type of fat in your blood called triglycerides, high blood pressure and an increase in your blood sugar.</li><li>&nbsp;Combination of fever, flu-like symptoms, sore throat, or any other infection with very low white blood cell count, a condition called agranulocytosis.</li><li>&nbsp;Bowel obstruction.</li><li>&nbsp;Increased blood creatine phosphokinase (a substance from the muscles).</li></ul><p><strong>Very rare: may affect up to 1 in 10,000 people</strong></p><ul><li>&nbsp;Severe rash, blisters, or red patches on the skin.</li><li>&nbsp;A severe allergic reaction (called anaphylaxis) which may cause difficulty in breathing or shock.</li><li>&nbsp;Rapid swelling of the skin, usually around the eyes, lips and throat (angioedema).</li><li>&nbsp;A serious blistering condition of the skin, mouth, eyes and genitals (Stevens-Johnson syndrome).</li><li>&nbsp;Inappropriate secretion of a hormone that controls urine volume.</li><li>&nbsp;Breakdown of muscle fibers and pain in muscles (rhabdomyolysis).</li></ul><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><ul><li>&nbsp;Skin rash with irregular red spots (erythema multiforme).</li><li>&nbsp;Serious, sudden allergic reaction with symptoms such as fever and blisters on the skin and peeling of the skin (toxic epidermal necrolysis).</li><li>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) which consists of flu-like symptoms with a rash, fever, swollen glands, and abnormal blood test results (including increased white blood cells (eosinophilia) and liver enzymes). See section 2.</li><li>&nbsp;Symptoms of withdrawal may occur in newborn babies of mothers that have used Seroquel during their pregnancy.</li><li>&nbsp;Stroke.</li></ul><p>The class of medicines to which Seroquel belongs can cause heart rhythm problems, which can be<br />serious and in severe cases may be fatal.<br />Some side effects are only seen when a blood test is taken. These include changes in the amount of<br />certain fats (triglycerides and total cholesterol) or sugar in the blood, changes in the amount of thyroid<br />hormones in your blood, increased liver enzymes, decreases in the number of certain types of blood<br />cells, decrease in the amount of red blood cells, increased blood creatine phosphokinase (a substance<br />in the muscles), decrease in the amount of sodium in the blood and increases in the amount of the<br />hormone prolactin in the blood. Increases in the hormone prolactin could in rare cases lead to the<br />following:<br />o Men and women to have swelling of the breasts and unexpectedly produce breast milk.</p><p>o Women to have no monthly period or irregular periods.<br />Your doctor may ask you to have blood tests from time to time.</p><p><strong>Additional side effects in children and adolescents</strong><br />The same side effects that may occur in adults may also occur in children and adolescents.<br />The following side effects have been seen more often in children and adolescents or have not been seen in adults:</p><p><strong>Very common: may affect more than 1 in 10 people</strong></p><ul><li>&nbsp;Increase in the amount of a hormone called prolactin, in the blood. Increases in the hormone prolactin could in rare cases lead to the following:</li></ul><p>o Boys and girls to have swelling of breasts and unexpectedly produce breast milk<br />o Girls to have no monthly period or irregular periods.</p><ul><li>&nbsp;Increased appetite.</li><li>&nbsp;Vomiting.</li><li>&nbsp;Abnormal muscle movements. These include difficulty starting muscle movements, shaking,</li></ul><p>feeling restless or muscle stiffness without pain.</p><ul><li>&nbsp;Increase in blood pressure.</li></ul><p><strong>Common: may affect up to 1 in 10 people</strong></p><ul><li>&nbsp;Feeling weak, fainting (may lead to falls).</li><li>&nbsp;Stuffy nose.</li><li>&nbsp;Feeling irritated.</li></ul><p><strong>Reporting of side effects</strong><br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the container after EXP. The<br />expiry date refers to the last day of that month.<br />Do not store above 30&deg;C.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is quetiapine. Seroquel tablets contain 25 mg, 100 mg, 200 mg or 300 mg<br />of quetiapine (as quetiapine fumarate).<br />&bull; The other ingredients are:<br />Tablet core: povidone, calcium hydrogen phosphate dihydrate, microcrystalline cellulose,<br />sodium starch glycollate Type A, lactose monohydrate, magnesium stearate.<br />Tablet coating: hypromellose, macrogol, titanium dioxide (E171). The 25 mg and 100 mg tablet<br />also contain iron oxide yellow (E172) and the 25 mg contain iron oxide red (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Seroquel 25 mg film-coated tablets are peach coloured, round biconvex and engraved with
SEROQUEL 25 on one side.
Seroquel 100 mg film-coated tablets are yellow, round biconvex and engraved with SEROQUEL
100 on one side.
Seroquel 200 mg film-coated tablets are white, round biconvex and engraved with SEROQUEL 200
on one side.
Seroquel 300 mg film-coated tablets are white, capsule-shaped and engraved with SEROQUEL on
one side and 300 on the other side.
Pack size of 60 tablets is registered for 100 mg, 200 mg. In addition, for 25 mg tablets pack size of
20 tablets is registered. For 300 mg tablets pack size of 30 is registered.
Not all pack sizes may be available.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Luye Pharma Limited, Surrey Technology Centre, 40 Occam Road, Surrey Research Park, Guilford<br />GU2 7YG, United Kingdom.<br /><strong>Manufacturer</strong><br />Manufactured by AstraZeneca Pharmaceutical Co. Ltd, No.2 Huangshan Road, Wuxi, Jiangsu, CN-214028, The People&rsquo;s Republic of China</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2020

Seroquel is a trade mark of the AstraZeneca group of companies.
© AstraZeneca 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي سيروكويل على مادة تسمى كويتيابين. وتنتمي إلى مجموعة من الدوية تسمى مضادات الذهان. يمكن استخدام سيروكويل لعلاج عدة أمراض، مثل:<br />&bull; الاكتئاب ثنائي القطب: حيث تشعر بالحزن. قد تجد أنك تشعر بالاكتئاب أو بالذنب أو تفتقر إلى الطاقة أو تفقد شهيتك أو لا<br />تستطيع النوم.<br />&bull; الهوس: حيث قد تشعر بالحماس الشديد أو السعادة أو الانفعال أو الحماسة أو النشاط المفرط أو ضعف الحكم بما في ذلك<br />العدوانية أو الاضطراب.<br />&bull; الفصام: حيث قد تسمع أو تشعر بأشياء غير موجودة أو تصدق أشياء غير صحيحة أو تشعر بالريبة أو القلق أو الارتباك أو الذنب<br />أو التوتر أو الاكتئاب على نحو غير طبيعي.</p><p><br />قد يستمر طبيبك في وصف دواء سيروكويل حتى عندما تشعر بتحسن .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول دواء سيروكويل في الحالات التالية:</strong></p><p>&nbsp;&bull; إذا كنت تعاني من حساسية تجاه كويتيابي ن أو أي من المكونات الخرى لهذا الدواء (المدرجة في القسم 6).<br />&bull; إذا كنت تتناول أي من الدوية التالية:<br />- بعض أدوية فيروس نقص المناعة البشرية<br />- أدوية الزول (للالتهابات الفطرية)<br />- اريثروميسين أو كلاريثروميسين (للالتهابات)<br />- نيفازودون (للاكتئاب).<br />إذا لم تكن متأكدًا، تحدث إلى طبيبك أو الصيدلي قبل تناول دواء سيروكويل.</p><p>&nbsp;</p><p><strong>المحاذير والإحتياطات</strong><br /><u>تحدث إلى طبيبك أو الصيدلي قبل تناول دواء سيروكويل:</u><br />&bull; إذا كنت أنت أو أحد أفراد أسرتك تعاني أو سبق أن عانيت من أي مشاكل في القلب، على سبيل المثال مشاكل في ضربات القلب أو<br />ضعف عضلة القلب أو التهاب القلب أو إذا كنت تتناول أي أدوية قد يكون لها تأثير على انتظام نبضات قلبك.<br />&bull; إذا كنت تعاني من انخفاض ضغط ال دم.<br />&bull; إذا أصبت بسكتة دماغية،&nbsp;خاصة إذا كنت مسنا<br />&bull; إذا كنت تعاني مشاكل في الكبد.<br />&bull; إذا سبق لك الإصابة ببنوبة.<br />&bull; إذا كنت تعاني من مرض السكري أو كنت معرضًا للإصابة بخطر الإصابة بمرض السكري. إذا قمت بذلك، فقد يقوم طبيبك<br />بفحص مست ويات السكر في الدم أثناء تناول دواء سيروكويل.<br />&bull; إذا كنت تعلم أن لديك مستويات منخفضة من خلايا الدم الب يضاء في فترة ماضية (والتي قد تكون أو لا تكون ناجمة عن أدوية<br />أخرى).<br />&bull; إذا كنت من كبار السن الم صابين بتدهور الوظائف العقلية (فقدان وظائف المخ). إذا كنت كذلك، فلا ينبغي تناول دواء سيروكويل<br />لن مجموعة الدوية التي ينتمي إليها دواء سيروكويل قد تزيد من خطر الإصابة بالسكتة الدماغية، أو في بعض الحالات خطر الوفاة ،<br />عند كبار السن المصابين بتدهور الوظائف العقلية.<br />&bull; إذا كنت شخصًا مسنًا مصابًا بمرض باركنسون.<br />&bull; إذا كنت أنت أو أي شخص آخر في عائلتك لديه تاريخ إصابة بالجلطات الدموية، حيث ارتبطت أدوية مثل هذه بتكوين جلطات الدم.<br />&bull; إذا كنت تعاني أو سبق أن عانيت من حالة توقف عن التنفس لفترات قصيرة أثناء نومك الليلي العادي (يسمى &quot;توقف التنفس أثناء<br />النوم&quot;)&nbsp;وتتناول أدوية تبطئ النشاط الطبيعي للدماغ (&quot;مثبطات&quot;).</p><p>&bull; إذا كنت تعاني أو سبق أن عانيت حالة لا يمكنك فيها إفراغ المثانة بالكامل )احتباس البول(، أو لديك تضخم في البروستاتا، أو<br />انسداد في المعاء، أو زيادة الضغط داخل عينك. تحدث هذه الحالات أحيانًا بسبب الدوية )المسماة &quot;مضادات الكولين&quot;( التي تؤثر<br />على طريقة عمل الخلايا العصبية لعلاج بعض الحالات الطبية.<br />&bull; إذا كان لديك تاريخ من تعاطي الكحول أو المخدرات .</p><p><u>أخبر طبيبك على الفور إذا واجهت أيًا مما يلي بعد تناول دواء سيروكويل:</u></p><ul><li>مزيج من الحمى، وتصلب شديد في العضلات، وتعرق أو انخفاض مستوى الوعي (اضطراب يسمى &quot;المتلازمة الخبيثة للدواء المضاد للذهان&quot;)ز&nbsp;قد تكون هناك حاجة إلى علاج طبي فوري.</li><li>عانيت حركات لا يمكن السيطرة عليها، خاصة في وجهك أو لسانك.</li><li>أصبت بدوار أو شعور شديد بالنعاس. وهذا يمكن أن يزيد من خطر الإصابة العرضية (السقوط) في المرضى المسنين.</li><li>نوبات.</li><li>انتصاب طويل المد ومؤلم (قساح).</li></ul><p>يمكن أن يكون يسبب هذا النوع من الدوية هذه الحالات.</p><p><u>أخبر طبيبك في أقرب وقت ممكن إذا عانيت أي مما يلي:</u></p><p>&bull; حمى أو أعراض شبيهة بالإنفلونزا أو التهاب الحلق أو أي عدوى أخرى ، حيث يمكن أن يكون ذلك نتيجة لانخفاض شديد في عدد<br />خلايا الدم البيضاء، مما قد يتطلب إيقاف تناول سيروكويل و/ أو إعطاء العلاج.<br />&bull; الإمساك مع آلام البطن المستمرة، أو الإمساك الذي لم يستجب للعلاج، حيث قد يؤدي ذلك إلى انسداد أكثر خطورة في المعاء.<br />&bull;<strong> خواطر انتحارية وتفاقم حالة الاكتئاب لديك.</strong></p><p>إذا كنت تعاني من الاكتئاب، فقد تراودك أحيانا&nbsp;أفكار لإيذاء نفسك أو الانتحار. وقد تزيد عند بدء العلاج لأول مرة&nbsp;لأن هذه الدوية تستغرق وقتا&nbsp;حتى تظهر فعاليتها، عادة&nbsp;حوالي أسبوعين ولكن أحيانا أطول،&nbsp;قد تزداد هذه الفكار أيضا&nbsp;إذا توقفت فجأة عن تناول<br />الدواء&nbsp;الدواء. قد يكون من الرجح أن تفكر بهذه الطريقة إذا كنت ما زلت شابا يافعا,&nbsp;أظهرت المعلومات من التجارب السريرية زيادة خطر الأ فكار الانتحارية و / أو السلوك الانتحاري لدى الشباب الذين تقل أعمارهم عن 25 عاما&nbsp;والذين يعانون من الاكتئاب.إذا واجهتك أفكار بإيذاء نفسك أو الانتحار في أي وقت ، فاتصل بطبيبك أو اذهب إلى المستشفى على الفور. قد تجد أنه من المفيد أن تخبر صديقا مقربا انك تعاني من الاكتئاب،&nbsp;واطلب منه قراءة هذه النشرة. وربما عليك أن تطلب منهم إخبارك إذا كانوا يعتقدون أن اكتئابك يزداد سواءا،&nbsp;أو إذا كانوا قلقين بشأن التغييرات في سلوكك.</p><p dir="ltr"><strong>(SCARs)&nbsp;ردود الفعل السلبية الجلدية الشديدة</strong></p><p>أبلغ عن تفاعلات جانبية جلدية شديدة (SCARs)&nbsp;التي يمكن أن تكون مهددة للحياة أو قاتلة في حالات نادرة جدا&nbsp;مع العلاج باستخدام هذا الدواء،&nbsp;وتظهر أعراضها كما يلي:</p><ul><li>متلازمة ستيفنز جونسون (SJS)،&nbsp;وهي طفح جلدي واسع الانتشار مع ظهور بثور وتقشر الجلد، خاصة حول الفم والنف والعينين&nbsp;والعضاء التناسلية.</li><li>تنخر البشرة السمي (TEN)،&nbsp;وهو شكل أكثر حدة يسبب تقشرا واسعا للجلد.&nbsp;</li><li>يظهر التفاعل الدوائي مع فرط الحمضات وأعراض أجهزة الجسم (DRESS)،&nbsp;في أعراض شبيهة بالإنفل ونزا مع طفح جلدي وحمى&nbsp;وتضخم في الغدد ونتائج غير طبيعية لفحص الدم (بما في ذلك زيادة خلايا الدم البيضاء (فرط الحمضات) وإنزيمات الكبد).</li></ul><p>توقف عن استخدام دواء سيروكويل إذا ظهرت عليك هذه العراض واتصل بطبيبك أو اطلب العناية الطبية على الفور.</p><p><strong>زيادة الوزن</strong><br />لوحظ زيادة الوزن في المرض ى الذين يتناولون دواء سيروكويل. يجب عليك أنت وطبيبك متابعة وزنك بانتظام.</p><p><strong>الأطفال والمراهقون</strong><br />دواء سيروكويل غير مخصص لعلاج الطفال والمراهقين الذين تقل أعمارهم عن 18 عاما.</p><p><strong>تفاعل الأدوية الأخرى مع دواء سيروكويل</strong></p><p>أخبر طبيبك إذا كنت تتناول أو تناولت مؤخرا&nbsp;أو قد تتناول أي أدوية أخرى.</p><p>لا تتناول دواء سيروكويل إذا كنت تتناول أي من الدوية التالية:</p><p>&bull; بعض أدوية فيروس نقص المناعة البشرية.<br />&bull; أدوية الزول (للالتهابات الفطرية).<br />&bull; الاريثروميسين أو كلاريثروميسين (للالتهابات).<br />&bull; نيفازودون (للاكتئاب).</p><p>أخبر طبيبك إذا كنت تتناول أي من الدوية التالية:</p><p>&bull; أدوية الصرع (مثل الفينيتوين أو الكاربامازيبين).<br />&bull; أدوية ارتفاع ضغط الدم.<br />&bull; الباربيتورات (لصعوبة النوم).<br />&bull; ثيوريدازين أو الليثيوم(أدوية أخرى مضادة للذهان).</p><p>&bull;الأدوية التي لها تأثير على انتظام ضربات قلبك، على سبيل المثال، الأدوية التي يمكن أن تسبب اختلالا&nbsp;في الإلكتروليتات (مستوياتمنخفضة من البوتاسيوم أو المغنيسيوم)&nbsp;مثل مدرات البول(حبوب الماء) أو بعض المضادات الحيوية (أدوية لعلاج الالتهابات).&nbsp;</p><p>&bull; الأدوية التي يمكن أن تسبب الإمساك.</p><p>الأدوية (المسماة &quot;مضادات الكولين&quot;),&nbsp;التي تؤثر على طريقة عمل الخلايا العصبية لعلاج حالات مرضية معينة.</p><p>قبل التوقف عن تناول أي من الدوية الخاصة بك، يرجى التحدث الى طبيبك أولا.</p><p><strong>تفاعل دواء سيروكويل مع الطعام والشراب والكحول</strong></p><p>&bull; يمكن تناول دواء سيروكويل مع الطعام أو بدونه.</p><p>&bull; احذر من كمية الكحول التي تتناولها. حيث أ ن التأثير المشترك لدواء سيروكويل والكحول يمكن أن يجعلك تشعر بالنعاس.</p><p>&bull; لا تشرب عصير الجريب فروت فيما تتناول دواء سيروكويل. حيث يمكن أن يؤثر على طريقة عمل الدواء.</p><p><strong>الحمل والرضاعة</strong></p><p>إذا كنت حاملا أو مرضعة ، أو تعتقدين انك قد تكونين حاملا أو تخططين لإنجاب طفل، اسألي طبيبك أولا للحصول على المشورة قبل تناول هذا الدواء، يجب ألا تتناولي دواء سيروكويل أثناء الحمل إلا إذا ناقشتي ذلك مع طبيبك، لا ينبغي أن تتناولي دواء سيروكويل إذا كنت مرضعة.</p><p>قد تحدث العراض التالية المشابهة للانسحاب عند الطفال حديثي الولادة من المهات اللائي استخدمن دواء سيروكويل في الأشهر الثلاثة الأخيرة (الأشهر الثلاثة الخيرة من الحمل): الاهتزاز ، وتيبس العضلات و/ أو&nbsp;الضعف، والنعاس، والتوتر، ومشاكل التنفس، وصعوبة في التغذية. إذا أصيب طفلك بأي من هذه العراض، فقد تحتاجي ن إلى الاتصال بطبيبك.</p><p><strong>القيادة واستعمال الماكينات</strong><br />قد تؤدي القراص التي تتناولها إلى شعورك بالنعاس. لا تقود السيارة أو تستخدم أي أدوات أو آلات حتى تعرف كيف تؤثر هذه القراص عليك.</p><p><strong>يحتوي دواء سيروكويل على اللاكتوز</strong></p><p>يحتوي دواء سيروكويل على اللاكتوز وهو نوع من السكر. إذا أخبرك طبيبك أن لديك حساسية تجاه بعض السكريات، تحدث إلى طبيبك<br />أولا قبل تناول هذا الدواء.</p><p><strong>يحتوي دواء سيروكويل على الصوديوم</strong></p><p>يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملغ) لكل قرص، وهذا يعني بشكل أساسي أنه &quot;خالٍ من الصوديوم&quot;.</p><p><strong>التأثير على اختبارات تحليل البول للكشف عن التعاطي</strong></p><p>إذا كنت تخضع لتحليل البول لكشف عن التعاطي، فقد يؤدي تناول دواء سيروكويل إلى نتائج إيجابية لمادة الميثادون أو بعض الدوية المضادة عند استخدام بعض طرق الاختبار، على الرغم من أنك قد لا تتناول الميثادون (TCAs) للاكتئاب المسماة مضادات الاكتئاب ثلاثية الحلقات أو مضادات الاكتئاب ثلاثية الحلقات . وإذا حدث ذلك، يمكنك إجراء اختبار أكثر تحديدا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دائما&nbsp;على تناول هذا الدواء تماما&nbsp;كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.&nbsp;سيقرر طبيبك جرعة البدء.</p><p>وستعتمد جرعة المداومة (الجرعة اليومية) على درجة مرضك واحتياجاتك ولكنها عادة ما تكون بين 150 مجم و 800 مجم.</p><p>&bull; ستتناول أقراصك مرة واحدة في اليوم في وقت النوم، أو مرتين في اليوم ، حسب مرضك.<br />&bull; ابتلع أقراصك كاملة مع شربة ماء.<br />&bull; يمكنك تناول أقراصك مع الطعام أو بدونه.<br />&bull; لا تشرب عصير الجريب فروت أثناء تناول طريقة تناول دواء سيروكويل. فمن الممكن أن يؤثر على طريقة عمل الدواء.<br />&bull; لا تتوقف عن تناول أقراصك حتى لو شعرت بتحسن، ما لم يخبرك طبيبك بذلك.</p><p><strong>مشاكل الكبد</strong></p><p>إذا كنت تعاني من مشاكل في الكبد، فقد يغير طبيبك جرعتك.</p><p><strong>كبار السن</strong></p><p>إذا كنت مسنا،&nbsp;فقد يغير طبيبك جرعتك.</p><p><strong>الاستخدم في حالات الأطفال والمراهقين</strong></p><p>يجب عدم استخدام دواء سيروكويل لعلاج الطفال والمراهقين الذين تقل أعمارهم عن 18 عاما.&nbsp;</p><p><strong>إذا تناولت جرعة سيروكويل زائدة عن الحاجة</strong></p><p>إذا تناولت جرعة من السيروكويل أكثر من التي وصفها لك الطبيب، فقد تشعر بالنعاس، وتشعر بالدوار، وتعاني من دقات قلب غير طبيعية.<br />اتصل بطبيبك أو أقرب مستشفى على الفور. واحتفظ بأقراص سيروكويل معك.</p><p><strong>إذا نسيت أن تتناول دواء سيروكويل</strong></p><p>إذا نسيت تناول جرعة، فتناولها حالما تتذكرها. إذا حان وقت تناول الجرعة التالية تقريبًا، انتظر حتى ذلك الحين. لا تتناول جرعة مضاعفة<br />لتعويض قرص منسي.</p><p>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p><p><strong>إذا توقفت عن تناول دواء سيروكويل</strong></p><p>إذا توقفت فجأة عن تناول دواء سيروكويل، فقد لا تتمكن من النوم (الأرق)،&nbsp;أو قد تشعر بالغثيان، أو قد تعاني من الصداع، والإسهال،وتشعر المرض (تصاب بالقيئ)، والدوخة أو التهيج، قد يقترح طبيبك تقليل الجرعة تدريجيا قبل التوقف عن العلاج.&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الدوية، يمكن أن يسبب هذا الدواء أثارا جانبية، على الرغم من عدم حذوثها لدى الجميع.&nbsp;</p><p><strong>شائعة جدًا:&nbsp;قد تظهر لدى أكثر من 1 من كل 10 أشخاص</strong></p><ul><li>دوار (قد يؤدي إلى السقوط)، صداع وجفاف الفم.&nbsp;</li><li>الشعور بالنعاس&nbsp;(وقد يزول ذلك مع مرور الوقت، فيما تستمر في تناول دواء سيروكويل) (قد يؤدي إلى السقوط).</li><li>&nbsp;تشمل أعراض التوقف (الأعراض التي تحدث عند التوقف عن تناول دواء سيروكويل) عدم القدرة على النوم (الأرق) والشعور بالغثيان والصداع والإسهال والمرض(القيء) والدوخة والتهيج. يُنصح بالتوقف تدريجيًا عن تناول الدواء على مدى فترة لا تقل عن أسبوع إلى أسبوعين.</li><li>&nbsp;زيادة الوزن.</li><li>&nbsp;حركات عضلية غير طبيعية. وتشمل الصعوبة في بدء حركة العضلات، أو الاهتزاز، أو الشعور بالضيق، أو تصلب العضلات دون ألم.</li><li>&nbsp;تغييرات في كمية بعض الدهون (الدهون الثلاثية والكوليسترول الكلي).&nbsp;</li></ul><p><strong>شائعة: قد تظهر لدى 1 من كل 10 أشخاص</strong></p><ul><li>سرعة ضربات القلب.&nbsp;</li><li>شعور بخفقان القلب أو تسارع الضربات أو زيادة خفقان القلب.&nbsp;</li><li>الإمساك، اضطراب المعدة (عسر الهضم).&nbsp;</li><li>الشعور بالضعف.&nbsp;</li><li>تورم الذراعين أو الساقين.&nbsp;</li><li>انخفاض ضغط الدم عند الوقوف. وقد يجعلك هذا تشعر بالدوار أو الاغماء&nbsp;(قد يؤدي إلى السقوط).&nbsp;</li><li>زيادة مستويات السكر في الدم.&nbsp;</li><li>تشوش الرؤية.</li><li>أحلام وكوابيس غير طبيعية.</li><li>زيادة الشعور بالجوع.&nbsp;</li><li>الشعور بالغضب.</li><li>اضطراب في الكلام واللغة.</li><li>خواطر انتحا رية وتفاقم حالة الاكتئاب لديك.&nbsp;</li><li>ضيق في&nbsp;التنفس.&nbsp;</li><li>القيء&nbsp;(خاصة عند كبار السن).</li><li>حمى.&nbsp;</li><li>تغييرات في كمية هرمونات الغدة الدرقية في الدم.&nbsp;</li><li>انخفاض في عدد أنواع معينة من خلايا الدم.</li><li>زيادة كمية إنزيمات الكبد المقاسة في الدم.&nbsp;</li><li>زيادة كمية هرمون البرولاكتين في الدم. زيادة هرمون البرولاكتين قد تؤدي في بعضالحالات النادرة إلى ما يلي:&nbsp;</li></ul><p>oانتفاخ الثديين لدى الرجال والنساء وإفراز حليب الثدي&nbsp;بشكل غير متوقع.<br />o&nbsp;عدم انتظام أو غياب الدورة الشهرية لدى النساء.</p><p><strong>غير شائعة: قد تظهر لدى 1 من كل 100 شخص</strong></p><ul><li>نوبات.</li><li>ردود الفعل التحسسية التي قد تشمل الكتل المرتفعة (التقرحات) وتورم الجلد والتورم حول الفم.</li><li>أحاسيس مزعجة في الساقين (وتسمى أيضًا متلازمة تململ الساقين).</li><li>صعوبة في البلع.&nbsp;</li><li>حركات لا إرادية، خاصة في وجهك أو لسانك.</li><li>العجز الجنسي .</li><li>داء السكري.&nbsp;</li><li>تغير في النشاط الكهربائي للقلب يظهر على مخطط كهربية القلب (فترة كيو تي مطولة) &quot;تستغرق عضلة القلب وقتا أطول من المعتاد للشحن بين النبضات.</li><li>معدل ضربات القلب أبطأ من الطبيعي الذي قد يحدث عند بدء العلاج وقد يترافق مع انخفاض ضغط الدم والإغماء.</li><li>صعوبة في التبول.&nbsp;</li><li>الإغماء (قد يؤدي إلى السقوط).&nbsp;</li><li>احتقان الأنف.&nbsp;</li><li>انخفاض في كمية خلايا الدم الحمراء.&nbsp;</li><li>انخفاض كمية الصوديوم في الدم.&nbsp;</li><li>تفاقم مرض السكري الموجود مسبقا.</li></ul><p><strong>نادرة: قد تؤثر على شخصمن كل 1000 شخص</strong></p><ul><li>مزيج من ارتفاع درجة الحرارة (الحمى) والتعرق وتيبس العضلات والشعور بالنعاس الشديد أو الإغماء (اضطراب يسمى &quot; المتلازمة الخبيثة للدواء المضاد للذهان&quot;)</li><li>اصفرار الجلد والعينين (اليرقان).&nbsp;</li><li>التهاب الكبد (كباد).</li><li>انتصاب طويل المد ومؤلم&nbsp;(القُساح).&nbsp;</li><li>تورم الثدي والإنتاج غير المتوقع لحليب الثدي (ثر الحليب).</li><li>اضطراب الدورة الشهرية.&nbsp;</li><li>جلطات دموية في الوردة خاصة في الساقين (تشمل العراض تورم وألم واحمرار في الساق)، والتي قد تنتقل عبر الأ وعية الدموية الى الرئتين مسببة ألما في الصدر وصعوبة في التنفس، اذا لاحظت أيا من هذه الأعراض، فاطلب المشورة الطبية على الفور.</li><li>المشي أو التحدث أو تناول الطعام أو أي القيام بأي أنشطة أخرى أثناء النوم..&nbsp;</li><li>انخفاض درجة&nbsp;حرارة الجسم.&nbsp;</li><li>التهاب البنكرياس.&nbsp;</li><li>حالة (تُسمى &quot;متلازمة التمثيل الغذائي&quot;)&nbsp;حيث قد تعاني من مزيج من ثلاث أو أكثر مما يلي: زيادة الدهون حول البطن، وانخفاض &quot;الكوليسترول الجيد&quot; (HDL C)&quot; ،&nbsp;وزيادة في نوع من الدهون تسمى الدهون الثلاثية في الدم، وارتفاع ضغط الدم وزيادة نسبة السكر في الدم.</li><li>مزيج من الحمى، وأعراض تشبه أعراض النفلونزا، والتهاب الحلق، أو أي عدوى أخرى مع انخفاض شديد في عدد خلايا الدم البيضاء، وهي حالة تسمى ندرة المحببات.</li><li>انسداد الأمعاء.&nbsp;</li><li>زيادة فسفوكيناز الكرياتين في الدم (مادة من العضلات).&nbsp;</li></ul><p><strong>نادرة جدًا: قد تؤثر على شخصمن كل 10000 شخص</strong></p><ul><li>&nbsp;طفح جلدي شديد أو بثور أو بقع حمراء على الجلد</li><li>رد فعل تحسسي شديد (يسمى الحساسية المفرطة) والذي قد يسبب صعوبة في التنفس أو صدمة.</li><li>تورم سريع في الجلد، عادة حول العينين والشفتين والحلق (وذمة وعائية).</li><li>حالة ظهور بثور خطيرة في الجلد والفم والعينين والعضاء التناسلية (متلازمة ستيفنز جونسون). انظر القسم 2</li><li>إفراز غير مناسب للهرمون الذي يتحكم في حجم البول.</li><li>انهيار ألياف العضلات وآلام في العضلات (انحلال الربيدات).&nbsp;</li></ul><p><strong>غير معروف: لا يمكن تقدير معدل تكرار الحالات من البيانات المتاحة</strong></p><ul><li>طفح جلدي مع بقع حمراء غير منتظمة (حمامي عديدة الأشكال).</li><li>رد فعل تحسس ي خطير ومفاجئ مصحوب بأعراض مثل الحمى والبثور على الجلد وتقشر الجلد (انحلال البشرة النخري السام). انظر القسم2</li><li>تفاعل الد وية مع فرط الحمضات وأعراض أجهزة الجسم (DRESS)&nbsp;والتي تتكون من أعراض شبيهة بالإنفلونزا مع طفح جلدي&nbsp;وحمى وتضخم في الغدد ونتائج غير طبيعية لفحص الدم )بما في ذلك زيادة خلايا الدم البيضاء )فرط الحمضات( وإنزيمات الكبد). انظر القسم 2.</li><li>قد تحدث أعراض الانسحاب عند الطفال حديثي الو لادة من المهات اللائي استخدمن دواء سيروكويل أثناء الحمل.</li><li>سكتة.</li></ul><p><br />فئة الدوية التي ينتمي إليها سيروكويل يمكن أن تسبب مشاكل في ضربات القلب، والتي يمكن أن تكون خطيرة وفي الحالات الشديدة قد تكون<br />قاتلة.</p><p><br />تظهر بعض الثار الجانبية فقط عند إجراء فحص الدم. وتشمل التغيرات في كمية بعض الدهون (الدهون الثلاثية والكوليسترول الكلي) أو السكر في الدم، والتغيرات في كمية هرمونات الغدة الدرقية في الدم، وزيادة إنزيمات الكبد، وانخفاض عدد أنواع معينة من خلايا الدم ،<br />وانخفاض في نسبة الهرمونات الدرقية وانخفاض في كمية كريات الدم الحمراء، وزيادة فوسفوكيناز الكرياتين في الدم (مادة في العضلات)، وانخفاض في كمية الصوديوم في الدم وزيادة كمية هرمون البرولاكتين في الدم. يمكن أن تؤدي زيادة هرمون البرولاكتين في حالات نادرة إلى ما يلي:</p><p>-انتفاخ في الثدي لدى الرجال والنساء وإفراز حليب الثدي بشكل غير متوقع.</p><p>-عدم انتظام أو غياب الدورة الشهرية لدى السيدات .</p><p><strong>أعراض جانبية إضافية لدى الأطفال والمراهقين</strong></p><p><br />قد تحدث نفس الثار الجانبية التي قد تحدث عند البالغين أيضا عند الأطفال والمراهقين.</p><p><br />لوحظت الثار الجانبية التالية في كثير من الحيان عند الطفال والمراهقين ولم تظهر عند البالغين:</p><p><strong>شائعة جدًا: قد تظهر لدى أكثر من 1 من كل 10 أشخاص</strong></p><p>زيادة كمية هرمون يسمى البرولاكتين في الدم. يمكن أن تؤدي زيادة هرمون البرولاكتين في حالات نادرة إلى ما يلي:</p><p>o&nbsp;لدى الولاد والبنات انتفاخ في الثديين وإنتاج حليب الثدي بشكل غير متوقع.<br />o عدم انتظام أو غياب الدورة الشهرية للفتيات.</p><ul><li>زيادة الشهية.&nbsp;</li><li>التقيؤ.</li><li>حركات العضلات غير الطبيعية. يشمل هذا صعوبة بدء حركات العضلات أو الرجفة أو الشعور بعدم الراحة أو تيبس&nbsp;العضلات دون ألم.</li><li>ارتفاع ضغط الدم.&nbsp;</li></ul><p><br /><strong>شائعة: قد تظهر لدى 1 من كل 10 أشخاص</strong></p><ul><li>الشعور بالضعف و&nbsp;الإغماء (قد يؤدي إلى السقوط).&nbsp;</li><li>احتقان&nbsp;الأنف.&nbsp;</li><li>الشعور بالغضب.</li></ul><p><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا تفاقمت أي من الثار الجانبية، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، فيرجى إخبار طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدا&nbsp;عن أنظار ومتناول أيدي الطفال.</p><p>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الحاوية بعد تاريخ انتهاء الصلاحية<br />الخير من نفس الشهر.<br />لا يجوز تخزين الدواء في درجة حرارة تتجاوز 30 درجة مئوية.<br />لا تتخلص من الدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الدوية التي لم تعد تستخدمها. ومن<br />شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي كويتيابين. تحتوي أقراص دواء سيروكويل على 25 مجم، أو 100 مجم، أو 200 مجم أو 300 مجم من الكويتيابين<br />(على هيئة كويتيابين فومارات).</p><p>المكونات الخرى هي:&nbsp;</p><p>داخل القرص: البوفيدو ن، ثنائي هيدرات فوسفات هيدروجين الكالسيوم، السليلوز دقيق التبلور ، نشا الصوديوم جليكولات النوع<br />أ، مونوهيدرات اللاكتوز ، ستيرات المغنيسيوم.<br />غلاف القرص: هيدروكس ي بروبيل ميثيل سيللوز ، ماكروغول ، ثاني أكسيد التيتانيوم (E171)،&nbsp;يحتوي قرص 25 مجم و 100 مجم أيضا على أكسيد الحدبد الأصفر (E172) ويحتوي القرص 25 مجم على أكسيد الحديد الأحمر (E172).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص سيروكويل 25 مج م المغلفة بطبقة رقيقة بلون الخوخ، مستديرة محدبة من الجانبين ومحفورة برمز 25<br />على جانب واحد. SEROQUEL أقراص سيروكويل 100 مجم المغلفة بلون أصفر، مستديرة محدبة من الجانبين ومحفورة ب 100<br />على جانب واحد . SEROQUEL أقراص سيروكويل 200 مجم المغلفة ولونها أبيض، مستديرة محدبة من الجانبين ومحفورة برمز 200<br />على جانب واحد و 300 على الجانب الخر . SEROQUEL أقراص سيروكويل 300 مجم المغلفة ولونها أبيض، على شكل كبسولة ومحفورة ب<br />عبوة بحجم 60 قرصًا مسجلة من أجل 100 مجم و 200 مجم. علاوة على هذا، القراص 25 مجم مسجلة في عبوة بحجم 20 قرصا.</p><p>الأ قراص 300 مجم مسجلة في عبوة بحجم 30 قرصا.&nbsp;</p><p>قد لا تتوفر العبوات بجميع الأحجام.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>صاحب ترخيص التسويق</strong><br />&nbsp;شركة لوي فارما المحدودة، مركز سوري للتكنولوجيا، 40 شارع أوكام، سوري ريسيرتش بارك، جيلفورد GU2 7YG، المملكة المتحدة.</p><p><strong>الشركة المصنعة</strong><br />شركة أسترا زينيكا فا رماسيوتكال المحدودة، طريق هوانغشان، ووكسي، الصين.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر 2020 
سيروكويل هي علامة تجارية مسجلة لمجموعة شركات أسترا زينيكا.
AstraZeneca 2020 ©
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Seroquel 25 mg film-coated tablets
Seroquel 100 mg film-coated tablets
Seroquel 200 mg film-coated tablets
Seroquel 300 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Seroquel 25 mg contains 25 mg quetiapine (as quetiapine fumarate)
Seroquel 100 mg contains 100 mg quetiapine (as quetiapine fumarate)
Seroquel 200 mg contains 200 mg quetiapine (as quetiapine fumarate)
Seroquel 300 mg contains 300 mg quetiapine (as quetiapine fumarate)
Excipients with known effect:
Seroquel 25 mg contains 18 mg lactose (anhydrous) per tablet
Seroquel 100 mg contains 20 mg lactose (anhydrous) per tablet
Seroquel 200 mg contains 39 mg lactose (anhydrous) per tablet
Seroquel 300 mg contains 59 mg lactose (anhydrous) per tablet
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet
Seroquel 25 mg tablets are peach coloured, round biconvex and engraved with
SEROQUEL 25 on one side
Seroquel 100 mg tablets are yellow, round biconvex and engraved with
SEROQUEL 100 on one side
Seroquel 200 mg tablets are white, round biconvex and engraved with SEROQUEL
200 on one side
Seroquel 300 mg tablets are white, capsule-shaped and engraved with SEROQUEL
on one side and 300 on the other side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Seroquel is indicated for:</p><ul><li>&nbsp;treatment of schizophrenia.</li><li>&nbsp;treatment of bipolar disorder:</li></ul><p>- For the treatment of moderate to severe manic episodes in bipolar disorder<br />- For the treatment of major depressive episodes in bipolar disorder<br />- For the prevention of recurrence of manic or depressed episodes in patients with<br />bipolar disorder who previously responded to quetiapine treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Different dosing schedules exist for each indication. It must therefore be ensured<br />that patients receive clear information on the appropriate dosage for their condition.<br />Seroquel can be administered with or without food.</p><p><br /><u>Adults</u><br /><em>For the treatment of schizophrenia</em><br />For the treatment of schizophrenia, Seroquel should be administered twice a day.<br />The total daily dose for the first four days of therapy is 50 mg (Day 1), 100 mg<br />(Day 2), 200 mg (Day 3) and 300 mg (Day 4) From Day 4 onwards, the dose<br />should be titrated to the usual effective dose of 300 to 450 mg/day. Depending on<br />the clinical response and tolerability of the individual patient, the dose may be<br />adjusted within the range 150 to 750 mg/day.</p><p><br />For the treatment of moderate to severe manic episodes in bipolar disorder<br />For the treatment of manic episodes associated with bipolar disorder, Seroquel<br />should be administered twice a day. The total daily dose for the first four days of<br />therapy is 100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) and 400 mg (Day 4).<br />Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of<br />no greater than 200 mg/day.</p><p><br />The dose may be adjusted depending on clinical response and tolerability of the<br />individual patient, within the range of 200 to 800 mg/day. The usual effective dose<br />is in the range of 400 to 800 mg/day.</p><p><br />For the treatment of major depressive episodes in bipolar disorder<br />Seroquel should be administered once daily at bedtime. The total daily dose for the<br />first four days of therapy is 50 mg (Day 1), 100 mg (Day 2), 200 mg (Day 3) and<br />300 mg (Day 4). The recommended daily dose is 300 mg. In clinical trials, no<br />additional benefit was seen in the 600 mg group compared to the 300 mg group (see&nbsp;section 5.1).</p><p>Individual patients may benefit from a 600 mg dose. Doses greater<br />than 300 mg should be initiated by physicians experienced in treating bipolar<br />disorder. In individual patients, in the event of tolerance concerns, clinical trials<br />have indicated that dose reduction to a minimum of 200 mg could be considered.</p><p><em>For preventing recurrence in bipolar disorder</em><br />For preventing recurrence of manic, mixed or depressive episodes in bipolar<br />disorder, patients who have responded to quetiapine for acute treatment of bipolar<br />disorder should continue therapy at the same dose. The dose may be adjusted<br />depending on clinical response and tolerability of the individual patient, within the<br />range of 300 to 800 mg/day administered twice daily. It is important that the lowest<br />effective dose is used for maintenance therapy.</p><p><em>Elderly</em><br />As with other antipsychotics, Seroquel should be used with caution in the elderly,<br />especially during the initial dosing period. The rate of dose titration may need to be<br />slower, and the daily therapeutic dose lower, than that used in younger patients,<br />depending on the clinical response and tolerability of the individual patient. The<br />mean plasma clearance of quetiapine was reduced by 30 - 50% in elderly subjects<br />when compared to younger patients.<br />Efficacy and safety has not been evaluated in patients over 65 years with depressive<br />episodes in the framework of bipolar disorder.</p><p><em><u>Paediatric population</u></em><br />Seroquel is not recommended for use in children and adolescents below 18 years of<br />age, due to a lack of data to support use in this age group. The available evidence<br />from placebo-controlled clinical trials is presented in sections 4.4, 4.8, 5.1 and 5.2.<br /><em><u>Renal impairment</u></em><br />Dosage adjustment is not necessary in patients with renal impairment.<br /><em><u>Hepatic impairment</u></em><br />Quetiapine is extensively metabolised by the liver. Therefore, Seroquel should be<br />used with caution in patients with known hepatic impairment, especially during the<br />initial dosing period. Patients with known hepatic impairment should be started<br />with 25 mg/day. The dosage should be increased daily with increments of 25 - 50<br />mg/day until an effective dosage, depending on the clinical response and<br />tolerability of the individual patient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients of this product.
Concomitant administration of cytochrome P450 3A4 inhibitors, such as HIVprotease
inhibitors, azole-antifungal agents, erythromycin, clarithromycin and
nefazodone, is contraindicated (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As Seroquel has several indications, the safety profile should be considered with<br />respect to the individual patient&rsquo;s diagnosis and the dose being administered.<br /><u>Paediatric population</u><br />Quetiapine is not recommended for use in children and adolescents below 18 years<br />of age, due to a lack of data to support use in this age group. Clinical trials with<br />quetiapine have shown that in addition to the known safety profile identified in<br />adults (see section 4.8), certain adverse events occurred at a higher frequency in<br />children and adolescents compared to adults (increased appetite, elevations in<br />serum prolactin, vomiting, rhinitis and syncope), or may have different implications<br />for children and adolescents (extrapyramidal symptoms and irritability) and one<br />was identified that has not been previously seen in adult studies (increases in blood<br />pressure). Changes in thyroid function tests have also been observed in children and<br />adolescents.<br />Furthermore, the long-term safety implications of treatment with quetiapine on<br />growth and maturation have not been studied beyond 26 weeks. Long-term<br />implications for cognitive and behavioural development are not known.<br />In placebo-controlled clinical trials with children and adolescent patients,<br />quetiapine was associated with an increased incidence of extrapyramidal symptoms<br />(EPS) compared to placebo in patients treated for schizophrenia, bipolar mania and<br />bipolar depression (see section 4.8).<br /><u>Suicide/suicidal thoughts or clinical worsening</u><br />Depression in bipolar disorder is associated with an increased risk of suicidal<br />thoughts, self-harm and suicide (suicide-related events). This risk persists until<br />significant remission occurs. As improvement may not occur during the first few<br />weeks or more of treatment, patients should be closely monitored until such<br />improvement occurs. It is general clinical experience that the risk of suicide may<br />increase in the early stages of recovery.</p><p>In addition, physicians should consider the potential risk of suicide-related events<br />after abrupt cessation of quetiapine treatment, due to the known risk factors for the<br />disease being treated.<br />Other psychiatric conditions for which quetiapine is prescribed can also be<br />associated with an increased risk of suicide related events. In addition, these<br />conditions may be co-morbid with major depressive episodes. The same<br />precautions observed when treating patients with major depressive episodes should<br />therefore be observed when treating patients with other psychiatric disorders.<br />Patients with a history of suicide related events, or those exhibiting a significant<br />degree of suicidal ideation prior to commencement of treatment are known to be at<br />greater risk of suicidal thoughts or suicide attempts, and should receive careful<br />monitoring during treatment. A meta analysis of placebo controlled clinical trials of<br />antidepressant drugs in adult patients with psychiatric disorders showed an&nbsp;</p><p>increased risk of suicidal behaviour with antidepressants compared to placebo in<br />patients less than 25 years old.<br />Close supervision of patients and in particular those at high risk should accompany<br />drug therapy especially in early treatment and following dose changes. Patients<br />(and caregivers of patients) should be alerted about the need to monitor for any<br />clinical worsening, suicidal behaviour or thoughts and unusual changes in<br />behaviour and to seek medical advice immediately if these symptoms present.<br />In shorter-term placebo controlled clinical studies of patients with major depressive<br />episodes in bipolar disorder an increased risk of suicide-related events was<br />observed in young adult patients (younger than 25 years of age) who were treated<br />with quetiapine as compared to those treated with placebo (3.0% vs. 0%,<br />respectively).</p><p>A population-based retrospective study of quetiapine<br />for the treatment of patients with major depressive<br />disorder showed an increased risk of self-harm and<br />suicide in patients aged 25 to 64 years without a<br />history of self-harm during use of quetiapine with<br />other antidepressants&nbsp;</p><p><br /><u>Metabolic risk</u><br />Given the observed risk for worsening of their metabolic profile, including changes<br />in weight, blood glucose (see hyperglycaemia) and lipids, which was seen in<br />clinical studies, patients&rsquo; metabolic parameters should be assessed at the time of<br />treatment initiation and changes in these parameters should be regularly controlled<br />for during the course of treatment. Worsening in these parameters should be<br />managed as clinically appropriate (see also section 4.8).<br /><u>Extrapyramidal symptoms</u><br />In placebo controlled clinical trials of adult patients quetiapine was associated with<br />an increased incidence of extrapyramidal symptoms (EPS) compared to placebo in<br />patients treated for major depressive episodes in bipolar disorder (see sections 4.8<br />and 5.1).<br />The use of quetiapine has been associated with the development of akathisia,<br />characterised by a subjectively unpleasant or distressing restlessness and need to<br />move often accompanied by an inability to sit or stand still. This is most likely to<br />occur within the first few weeks of treatment. In patients who develop these<br />symptoms, increasing the dose may be detrimental.<br /><u>Tardive dyskinesia</u><br />If signs and symptoms of tardive dyskinesia appear, dose reduction or<br />discontinuation of quetiapine should be considered. The symptoms of tardive<br />dyskinesia can worsen or even arise after discontinuation of treatment (see section<br />4.8).<br /><u>Somnolence and dizziness</u><br />Quetiapine treatment has been associated with somnolence and related symptoms,<br />such as sedation (see section 4.8). In clinical trials for treatment of patients with<br />bipolar depression, onset was usually within the first 3 days of treatment and was<br />predominantly of mild to moderate intensity. Patients experiencing somnolence of<br />severe intensity may require more frequent contact for a minimum of 2 weeks from<br />onset of somnolence, or until symptoms improve and treatment discontinuation<br />may need to be considered.</p><p><u>Orthostatic hypotension</u><br />Quetiapine treatment has been associated with orthostatic hypotension and related<br />dizziness (see section 4.8) which, like somnolence has onset usually during the<br />initial dose-titration period. This could increase the occurrence of accidental injury<br />(fall), especially in the elderly population. Therefore, patients should be advised to<br />exercise caution until they are familiar with the potential effects of the medication.<br />Quetiapine should be used with caution in patients with known cardiovascular<br />disease, cerebrovascular disease, or other conditions predisposing to hypotension.<br />Dose reduction or more gradual titration should be considered if orthostatic<br />hypotension occurs, especially in patients with underlying cardiovascular disease.<br /><u>Sleep apnoea syndrome</u><br />Sleep apnoea syndrome has been reported in patients using quetiapine. In patients<br />receiving concomitant central nervous system depressants and who have a history<br />of or are at risk for sleep apnoea, such as those who are overweight/obese or are<br />male, quetiapine should be used with caution.<br /><u>Seizures</u><br />In controlled clinical trials there was no difference in the incidence of seizures in<br />patients treated with quetiapine or placebo. No data is available about the incidence<br />of seizures in patients with a history of seizure disorder. As with other<br />antipsychotics, caution is recommended when treating patients with a history of<br />seizures (see section 4.8).<br /><u>Neuroleptic malignant syndrome</u><br />Neuroleptic malignant syndrome has been associated with antipsychotic treatment,<br />including quetiapine (see section 4.8). Clinical manifestations include<br />hyperthermia, altered mental status, muscular rigidity, autonomic instability, and<br />increased creatine phosphokinase. In such an event, quetiapine should be<br />discontinued and appropriate medical treatment given.<br /><u>Severe neutropenia and agranulocytosis</u><br />Severe neutropenia (neutrophil count &lt;0.5 x 109/L) has been reported in quetiapine<br />clinical trials. Most cases of severe neutropenia have occurred within a couple of<br />months of starting therapy with quetiapine. There was no apparent dose<br />relationship. During post-marketing experience, some cases were fatal. Possible<br />risk factors for neutropenia include pre-existing low white blood cell count (WBC)<br />and history of drug induced neutropenia. However, some cases occurred in patients<br />without pre-existing risk factors. Quetiapine should be discontinued in patients with<br />a neutrophil count &lt;1.0 x 109/L. Patients should be observed for signs and<br />symptoms of infection and neutrophil counts followed (until they exceed<br />1.5 x 109/L) (see section 5.1).<br />Neutropenia should be considered in patients presenting with infection or fever,<br />particularly in the absence of obvious predisposing factor(s), and should be<br />managed as clinically appropriate.<br />Patients should be advised to immediately report the appearance of signs/symptoms<br />consistent with agranulocytosis or infection (e.g. fever, weakness, lethargy, or sore</p><p>throat) at any time during Seroquel therapy. Such patients should have a WBC<br />count and an absolute neutrophil count (ANC) performed promptly, especially in<br />the absence of predisposing factors.<br /><u>Anti-cholinergic (muscarinic) effects</u><br />Norquetiapine, an active metabolite of quetiapine, has moderate to strong affinity<br />for several muscarinic receptor subtypes. This contributes to ADRs reflecting anticholinergic<br />effects when quetiapine is used at recommended doses, when used<br />concomitantly with other medications having anti-cholinergic effects, and in the<br />setting of overdose. Quetiapine should be used with caution in patients receiving<br />medications having anti-cholinergic (muscarinic) effects. Quetiapine should be<br />used with caution in patients with a current diagnosis or prior history of urinary<br />retention, clinically significant prostatic hypertrophy, intestinal obstruction or<br />related conditions, increased intraocular pressure or narrow angle glaucoma (see<br />sections 4.5, 4.8, 5.1 and 4.9).<br /><u>Interactions</u><br />See section 4.5.<br />Concomitant use of quetiapine with a strong hepatic enzyme inducer such as<br />carbamazepine or phenytoin substantially decreases quetiapine plasma<br />concentrations, which could affect the efficacy of quetiapine therapy. In patients<br />receiving a hepatic enzyme inducer, initiation of quetiapine treatment should only<br />occur if the physician considers that the benefits of quetiapine outweigh the risks of<br />removing the hepatic enzyme inducer. It is important that any change in the inducer<br />is gradual, and if required, replaced with a non-inducer (e.g. sodium valproate).<br /><u>Weight</u><br />Weight gain has been reported in patients who have been treated with quetiapine,<br />and should be monitored and managed as clinically appropriate as in accordance<br />with utilised antipsychotic guidelines (see sections 4.8 and 5.1).<br /><u>Hyperglycaemia</u><br />Hyperglycaemia and/or development or exacerbation of diabetes occasionally<br />associated with ketoacidosis or coma has been reported rarely, including some fatal<br />cases (see section 4.8). In some cases, a prior increase in body weight has been<br />reported which may be a predisposing factor. Appropriate clinical monitoring is<br />advisable in accordance with utilised antipsychotic guidelines. Patients treated with<br />any antipsychotic agent including quetiapine, should be observed for signs and<br />symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and<br />weakness) and patients with diabetes mellitus or with risk factors for diabetes<br />mellitus should be monitored regularly for worsening of glucose control. Weight<br />should be monitored regularly.<br /><u>Lipids</u><br />Increases in triglycerides, LDL and total cholesterol, and decreases in HDL<br />cholesterol have been observed in clinical trials with quetiapine (see section 4.8).<br />Lipid changes should be managed as clinically appropriate.</p><p><u>QT prolongation</u><br />In clinical trials and use in accordance with the SPC, quetiapine was not associated<br />with a persistent increase in absolute QT intervals. In post-marketing, QT<br />prolongation was reported with quetiapine at the therapeutic doses (see section 4.8)<br />and in overdose (see section 4.9). As with other antipsychotics, caution should be<br />exercised when quetiapine is prescribed in patients with cardiovascular disease or<br />family history of QT prolongation. Also, caution should be exercised when<br />quetiapine is prescribed either with medicines known to increase QT interval or<br />with concomitant neuroleptics, especially in the elderly, in patients with congenital<br />long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or<br />hypomagnesaemia (see section 4.5).<br /><u>Cardiomyopathy and myocarditis</u><br />Cardiomyopathy and myocarditis have been reported in clinical trials and during<br />the post-marketing experience, however, a causal relationship to quetiapine has not<br />been established. Treatment with quetiapine should be reassessed in patients with<br />suspected cardiomyopathy or myocarditis.</p><p><u>Severe Cutaneous Adverse Reactions:</u><br />Severe cutaneous adverse reactions (SCARs),<br />including Stevens-Johnson syndrome (SJS), toxic<br />epidermal necrolysis (TEN) and drug reaction with<br />eosinophilia and systemic symptoms (DRESS) which<br />can be life-threatening or fatal have been reported<br />very rarely with quetiapine treatment. SCARs<br />commonly present as a combination of the<br />following symptoms: extensive cutaneous rash or<br />exfoliative dermatitis, fever, lymphadenopathy and<br />possible eosinophilia. If signs and symptoms<br />suggestive of these severe skin reactions appear,<br />quetiapine should be withdrawn immediately and<br />alternative treatment should be considered.</p><p><br /><u>Withdrawal</u><br />Acute withdrawal symptoms such as insomnia, nausea, headache, diarrhoea,<br />vomiting, dizziness and irritability have been described after abrupt cessation of<br />quetiapine. Gradual withdrawal over a period of at least one to two weeks is<br />advisable (see section 4.8).<br /><u>Elderly patients with dementia-related psychosis</u><br />Quetiapine is not approved for the treatment of dementia-related psychosis.<br />An approximately 3-fold increased risk of cerebrovascular adverse events has been<br />seen in randomised placebo controlled trials in the dementia population with some<br />atypical antipsychotics. The mechanism for this increased risk is not known. An<br />increased risk cannot be excluded for other antipsychotics or other patient<br />populations. Quetiapine should be used with caution in patients with risk factors for<br />stroke.<br />In a meta-analysis of atypical antipsychotics, it has been reported that elderly<br />patients with dementia-related psychosis are at an increased risk of death compared<br />to placebo. In two 10-week placebo-controlled quetiapine studies in the same<br />patient population (n=710); mean age: 83 years; range: 56-99 years) the incidence<br />of mortality in quetiapine treated patients was 5.5% versus 3.2% in the placebo<br />group. The patients in these trials died from a variety of causes that were consistent<br />with expectations for this population.</p><p><u>Elderly patients with Parkinson&rsquo;s disease(PD)/parkinsonism:</u><br />A population-based retrospective study of<br />quetiapine for the treatment of patients with MDD,<br />showed an increased risk of death during use of<br />quetiapine in patients aged &gt;65 years. This<br />association was not present when patients with PD<br />were removed from the analysis. Caution should be<br />exercised if quetiapine is prescribed to elderly<br />patients with PD.</p><p><br /><u>Dysphagia</u><br />Dysphagia (see section 4.8) has been reported with quetiapine. Quetiapine should<br />be used with caution in patients at risk for aspiration pneumonia.<br /><u>Constipation and intestinal obstruction</u><br />Constipation represents a risk factor for intestinal obstruction. Constipation and<br />intestinal obstruction have been reported with quetiapine (see section 4.8). This<br />includes fatal reports in patients who are at higher risk of intestinal obstruction,</p><p>including those that are receiving multiple concomitant medications that decrease<br />intestinal motility and/or may not report symptoms of constipation. Patients with<br />intestinal obstruction/ileus should be managed with close monitoring and urgent<br />care.<br /><u>Venous thromboembolism (VTE)</u><br />Cases of venous thromboembolism (VTE) have been reported with antipsychotic<br />drugs. Since patients treated with antipsychotics often present with acquired risk<br />factors for VTE, all possible risk factors for VTE should be identified before and<br />during treatment with quetiapine and preventive measures undertaken.<br /><u>Pancreatitis</u><br />Pancreatitis has been reported in clinical trials and during post marketing<br />experience. Among post marketing reports, while not all cases were confounded by<br />risk factors, many patients had factors which are known to be associated with<br />pancreatitis such as increased triglycerides (see section 4.4), gallstones, and alcohol<br />consumption.<br /><u>Additional information</u><br />Quetiapine data in combination with divalproex or lithium in acute moderate to<br />severe manic episodes is limited; however, combination therapy was well tolerated<br />(see section 4.8 and 5.1). The data showed an additive effect at week 3.<br /><u>Lactose</u><br />Seroquel tablets contain lactose. Patients with rare hereditary problems of galactose<br />intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should<br />not take this medicine.<br /><u>Misuse and abuse</u><br />Cases of misuse and abuse have been reported. Caution may be needed when<br />prescribing quetiapine to patients with a history of alcohol or drug abuse.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given the primary central nervous system effects of quetiapine, quetiapine should<br />be used with caution in combination with other centrally acting medicinal products<br />and alcohol.<br />Caution should be exercised treating patients receiving other medications having<br />anti-cholinergic (muscarinic) effects (see section 4.4).<br />Cytochrome P450 (CYP) 3A4 is the enzyme that is primarily responsible for the<br />cytochrome P450 mediated metabolism of quetiapine. In an interaction study in<br />healthy volunteers, concomitant administration of quetiapine (dosage of 25 mg)<br />with ketoconazole, a CYP3A4 inhibitor, caused a 5- to 8-fold increase in the AUC<br />of quetiapine. On the basis of this, concomitant use of quetiapine with CYP3A4<br />inhibitors is contraindicated. It is also not recommended to consume grapefruit<br />juice while on quetiapine therapy.</p><p>In a multiple dose trial in patients to assess the pharmacokinetics of quetiapine<br />given before and during treatment with carbamazepine (a known hepatic enzyme<br />inducer), co-administration of carbamazepine significantly increased the clearance<br />of quetiapine. This increase in clearance reduced systemic quetiapine exposure (as<br />measured by AUC) to an average of 13% of the exposure during administration of<br />quetiapine alone; although a greater effect was seen in some patients. As a<br />consequence of this interaction, lower plasma concentrations can occur, which<br />could affect the efficacy of quetiapine therapy. Co-administration of quetiapine and<br />phenytoin (another microsomal enzyme inducer) caused a greatly increased<br />clearance of quetiapine by approx. 450%. In patients receiving a hepatic enzyme<br />inducer, initiation of quetiapine treatment should only occur if the physician<br />considers that the benefits of quetiapine outweigh the risks of removing the hepatic<br />enzyme inducer. It is important that any change in the inducer is gradual, and if<br />required, replaced with a non-inducer (e.g. sodium valproate) (see section 4.4).<br />The pharmacokinetics of quetiapine were not significantly altered by coadministration<br />of the antidepressants imipramine (a known CYP 2D6 inhibitor) or<br />fluoxetine (a known CYP 3A4 and CYP 2D6 inhibitor).<br />The pharmacokinetics of quetiapine were not significantly altered by coadministration<br />of the antipsychotics risperidone or haloperidol. Concomitant use of<br />quetiapine and thioridazine caused an increased clearance of quetiapine with<br />approx. 70%.<br />The pharmacokinetics of quetiapine were not altered following co-administration<br />with cimetidine.<br />The pharmacokinetics of lithium were not altered when co-administered with<br />quetiapine.<br />In a 6-week, randomised, study of lithium and Seroquel XL versus placebo and<br />Seroquel XL in adult patients with acute mania, a higher incidence of<br />extrapyramidal related events (in particular tremor), somnolence, and weight gain<br />were observed in the lithium add-on group compared to the placebo add-on group<br />(see section 5.1).<br />The pharmacokinetics of sodium valproate and quetiapine were not altered to a<br />clinically relevant extent when co-administered. A retrospective study of children<br />and adolescents who received valproate, quetiapine, or both, found a higher<br />incidence of leucopenia and neutropenia in the combination group versus the<br />monotherapy groups.<br />Formal interaction studies with commonly used cardiovascular medicinal products<br />have not been performed.<br />Caution should be exercised when quetiapine is used concomitantly with medicinal<br />products known to cause electrolyte imbalance or to increase QT interval.<br />There have been reports of false positive results in enzyme immunoassays for<br />methadone and tricyclic antidepressants in patients who have taken quetiapine.</p><p>Confirmation of questionable immunoassay screening results by an appropriate<br />chromatographic technique is recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em><br /><em>First trimester</em><br />The moderate amount of published data from exposed pregnancies (<u>i.e. between<br />300-1000 pregnancy outcomes),</u> including individual reports and some<br />observational studies do not suggest an increased risk of malformations due to<br />treatment. However, based on all available data, a definite conclusion cannot be<br />drawn. Animal studies have shown reproductive toxicity (see section 5.3).<br />Therefore, quetiapine should only be used during pregnancy if the benefits justify<br />the potential risks.<br /><em>Third trimester</em><br />Neonates exposed to antipsychotics (including quetiapine) during the third trimester<br />of pregnancy are at risk of adverse reactions including extrapyramidal and/or<br />withdrawal symptoms that may vary in severity and duration following delivery.<br />There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence,<br />respiratory distress, or feeding disorder. Consequently, newborns should be<br />monitored carefully.<br /><em><u>Breast-feeding</u></em><br />Based on very limited data from published reports on quetiapine excretion into<br />human breast milk, excretion of quetiapine at therapeutic doses appears to be<br />inconsistent. Due to lack of robust data, a decision must be made whether to<br />discontinue breast-feeding or to discontinue Seroquel therapy taking into account<br />the benefit of breast-feeding for the child and the benefit of therapy for the woman.<br /><u><em>Fertility</em></u><br />The effects of quetiapine on human fertility have not been assessed. Effects related<br />to elevated prolactin levels were seen in rats, although these are not directly<br />relevant to humans (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given its primary central nervous system effects, quetiapine may interfere with<br />activities requiring mental alertness. Therefore, patients should be advised not to<br />drive or operate machinery, until individual susceptibility to this is known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported Adverse Drug Reactions (ADRs) with quetiapine<br />(&ge;10%) are somnolence, dizziness, headache, dry mouth, withdrawal<br />(discontinuation) symptoms, elevations in serum triglyceride levels, elevations in<br />total cholesterol (predominantly LDL cholesterol), decreases in HDL cholesterol,<br />weight gain, decreased haemoglobin and extrapyramidal symptoms.<br />The incidences of ADRs associated with quetiapine therapy, are tabulated below<br />(Table 1) according to the format recommended by the Council for International<br />Organizations of Medical Sciences (CIOMS III Working Group; 1995).</p><p><strong>Table 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADRs associated with quetiapine therapy</strong></p><p>&nbsp;</p><p>The frequencies of adverse events are ranked according to the following: Very common (&ge;1/10), common (&ge;1/100, &lt;1/10), uncommon (&ge;1/1000, &lt;1/100), rare (&ge;1/10,000, &lt;1/1000), very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>SOC</strong></p></td><td><p><strong>Very</strong></p><p><strong>Common</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Very Rare</strong></p></td><td><p><strong>Not known</strong></p></td></tr><tr><td><p><em>Blood and lymphatic system disorders</em></p></td><td><p>Decreased haemoglobin</p><p><sup>22</sup></p></td><td><p>Leucopenia <sup>1,</sup></p><p><sup>28</sup>, decreased neutrophil count,</p><p>eosinophils increased27</p></td><td><p>Neutropenia<sup>1</sup>, Thrombocyto penia, Anaemia, platelet count decreased13</p></td><td><p>Agranulocytosi s<sup>26</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em>Immune system disorders</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Hypersensiti vity (including allergic skin reactions)</p></td><td><p>&nbsp;</p></td><td><p>Anaphylact ic reaction<sup>5</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em>Endocrine disorders</em></p></td><td><p>&nbsp;</p></td><td><p>Hyperprolact inaemia<sup>15</sup>, decreases in total T<sub>4</sub> <sup>24</sup>, decreases in free T<sub>4</sub> <sup>24</sup>, decreases in total T<sub>3</sub> <sup>24</sup>, increases in TSH <sup>24</sup></p></td><td><p>Decreases in free T3 24, Hypothyroidi sm21</p></td><td><p>&nbsp;</p></td><td><p>Inappropria te antidiuretic hormone secretion</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em>Metabolism and nutritional disorders</em></p></td><td><p>Elevations in serum triglyceride levels<sup> 10,30</sup></p><p>Elevations in total cholesterol (predominant ly LDL cholesterol)</p><p><sup>11,30</sup></p><p>&nbsp;</p><p>Decreases in HDL cholesterol</p><p><sup>17,30</sup>, Weight</p></td><td><p>Increased appetite, blood glucose increased to hyperglycae</p><p>mic levels <sup>6</sup>,</p><p><sup>30</sup></p></td><td><p>Hyponatraem ia <sup>19</sup>,</p><p>Diabetes</p><p>Mellitus<sup> 1,5</sup></p><p>Exacerbation of pre- existing diabetes</p></td><td><p>Metabolic syndrome<sup>29</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="width:208px"><p><strong>SOC</strong></p></td><td style="width:143px"><p><strong>Very</strong></p><p><strong>Common</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Very Rare</strong></p></td><td><p><strong>Not known</strong></p></td></tr><tr><td style="width:208px"><p>&nbsp;</p></td><td style="width:143px"><p>gain<sup> 8,30</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="width:208px"><p><em>Psychiatric disorders</em></p></td><td style="width:143px"><p>&nbsp;</p></td><td><p>Abnormal dreams and nightmares, Suicidal ideation and suicidal</p><p>behaviour<sup>20</sup></p></td><td><p>&nbsp;</p></td><td><p>Somnambulis m and related reactions such as sleep talking and sleep related eating disorder</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="width:208px"><p><em>Nervous system disorders</em></p></td><td style="width:143px"><p>Dizziness<sup> 4,</sup></p><p><sup>16</sup>,</p><p>somnolence</p><p><sup>2,16,</sup></p><p>headache, Extrapyramid al</p><p>symptoms<sup>1, 21</sup></p></td><td><p>Dysarthria</p></td><td><p>Seizure<sup> 1,</sup> Restless legs syndrome, Tardive dyskinesia<sup> 1,</sup></p><p><sup>5</sup>, Syncope</p><p><sup>4,16</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="width:208px"><p><em>Cardiac disorders</em></p></td><td style="width:143px"><p>&nbsp;</p></td><td><p>Tachycardia</p><p><sup>4,</sup></p><p>Palpitations<sup>23</sup></p></td><td><p>QT</p><p>prolongation</p><p><sup>1,12, 18</sup></p><p>Bradycardia<sup>3</sup></p><p><sup>2</sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="width:208px"><p><em>Eye </em><em>disorders</em></p></td><td style="width:143px"><p>&nbsp;</p></td><td><p>Vision blurred</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="width:208px"><p><em>Vascular disorders</em></p></td><td style="width:143px"><p>&nbsp;</p></td><td><p>Orthostatic hypotension</p><p><sup>4,16</sup></p></td><td><p>&nbsp;</p></td><td><p>Venous thromboemboli sm1</p></td><td><p>&nbsp;</p></td><td><p>Stroke 33</p></td></tr><tr><td style="width:208px"><p><em>Respiratory, thoracic and mediastinal disorder</em></p></td><td style="width:143px"><p>&nbsp;</p></td><td><p>Dyspnoea<sup> 23</sup></p></td><td><p>Rhinitis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="width:208px"><p><em>Gastrointesti nal disorders</em></p></td><td style="width:143px"><p>Dry mouth</p></td><td><p>Constipation, dyspepsia, vomiting25</p></td><td><p>Dysphagia<sup>7</sup></p></td><td><p>Pancreatitis1, Intestinal obstruction/Ile us</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="width:208px"><p><em>Hepato- biliary disorders</em></p></td><td style="width:143px"><p>&nbsp;</p></td><td><p>Elevations in serum</p><p>alanine aminotransfe rase (ALT)3, Elevations in</p></td><td><p>Elevations in serum aspartate aminotransfe</p><p>rase (AST) 3</p></td><td><p>Jaundice5, Hepatitis</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>SOC</strong></p></td><td><p><strong>Very</strong></p><p><strong>Common</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Very Rare</strong></p></td><td><p><strong>Not known</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>gamma-GT</p><p>levels3</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em>Skin and subcutaneous tissue disorders</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Angioedem a5, Stevens- Johnson syndrome5</p></td><td><p>Toxic Epidermal Necrolysis, Erythema Multiforme,Drug Rash with Eosinophilia and<br />Systemic Symptoms (DRESS)</p></td></tr><tr><td><p><em>Musculoskele tal and connective tissue disorders</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Rhabdomy olysis</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em>Renal and urinary disorders</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Urinary retention</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em>Pregnancy, puerperium and perinatal conditions</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Drug withdrawal syndrome neonatal31</p></td></tr><tr><td><p><em>Reproductive system and breast disorders</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Sexual dysfunction</p></td><td><p>Priapism, galactorrhoea, breast swelling, menstrual disorder</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em>General disorders and</em></p><p><em>administratio n site conditions</em></p></td><td><p>Withdrawal ( discontinuati on)</p><p>symptoms<sup> 1,9</sup></p></td><td><p>Mild asthenia, peripheral oedema, irritability, pyrexia</p></td><td><p>&nbsp;</p></td><td><p>Neuroleptic malignant syndrome 1, hypothermia</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em>Investigation s</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Elevations in blood creatine phosphokinase</p><p>14</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>1.&nbsp;&nbsp;&nbsp;&nbsp; See section 4.4.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Somnolence may occur, usually during the first two weeks of treatment and generally resolves with the continued administration of quetiapine.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; Asymptomatic elevations (shift from normal to &gt;3 x ULN at any time) in serum transaminase (ALT, AST) or gamma-GT levels have been observed in some patients administered quetiapine. These elevations were usually reversible on continued quetiapine treatment.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp; As with other antipsychotics with alpha1 adrenergic blocking activity, quetiapine may commonly induce orthostatic hypotension, associated with dizziness, tachycardia and, in some patients, syncope, especially during the initial dose-titration period. (see section 4.4).</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp; Calculation of Frequency for these ADR&rsquo;s have been taken from post-marketing data only.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp; Fasting blood glucose &ge;126 mg/dL (&ge;7.0 mmol/L) or a non-fasting blood glucose &ge;200 mg/dL (&ge;11.1 mmol/L) on at least one occasion.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp; An increase in the rate of dysphagia with quetiapine vs. placebo was only observed in the clinical trials in bipolar depression.</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp; Based on &gt;7% increase in body weight from baseline. Occurs predominantly during the early weeks of treatment in adults.</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp; The following withdrawal symptoms have been observed most frequently in acute placebo- controlled, monotherapy clinical trials, which evaluated discontinuation symptoms: insomnia,</p><p>nausea, headache, diarrhoea, vomiting, dizziness, and irritability. The incidence of these reactions had decreased significantly after 1 week post-discontinuation.</p><p>10.&nbsp; &nbsp;Triglycerides &ge;200 mg/dL (&ge;2.258 mmol/L) (patients &ge;18 years of age) or &ge;150 mg/dL (&ge;1.694 mmol/L) (patients &lt;18 years of age) on at least one occasion.</p><p>11.&nbsp; &nbsp;Cholesterol &ge;240 mg/dL (&ge;6.2064 mmol/L) (patients &ge;18 years of age) or &ge;200 mg/dL</p><p>(&ge;5.172 mmol/L) (patients &lt;18 years of age) on at least one occasion. An increase in LDL cholesterol of &ge;30 mg/dL (&ge;0.769 mmol/L) has been very commonly observed. Mean change among patients who had this increase was 41.7 mg/dL (&ge;1.07 mmol/L).</p><p>12.&nbsp; &nbsp;See text below.</p><p>13.&nbsp; &nbsp;Platelets &le;100 x 109/L on at least one occasion.</p><p>14.&nbsp; &nbsp;Based on clinical trial adverse event reports of blood creatine phosphokinase increase not associated with neuroleptic malignant syndrome.</p><p>15.&nbsp; &nbsp;Prolactin levels (patients &gt;18 years of age): &gt;20 &mu;g/L (&gt;869.56 pmol/L) males; &gt;30 &mu;g/L (&gt;1304.34 pmol/L) females at any time.</p><p>16.&nbsp; &nbsp;May lead to falls.</p><p>17.&nbsp; &nbsp;HDL cholesterol: 40 mg/dL (1.025 mmol/L) males; 50 mg/dL (1.282 mmol/L) females at any time.</p><p>18.&nbsp; &nbsp;Incidence of patients who have a QTc shift from &lt;450 msec to &ge;450 msec with a &ge;30 msec</p><p>increase. In placebo-controlled trials with quetiapine the mean change and the incidence of patients who have a shift to a clinically significant level is similar between quetiapine and placebo.</p><p>19.&nbsp; &nbsp;Shift from &gt;132 mmol/L to &le;132 mmol/L on at least one occasion.</p><p>20.&nbsp; &nbsp;Cases of suicidal ideation and suicidal behaviours have been reported during quetiapine therapy or early after treatment discontinuation (see sections 4.4 and 5.1).</p><p>21.&nbsp; &nbsp;See section 5.1.</p><p>22.&nbsp; &nbsp;Decreased haemoglobin to &le;13 g/dL (8.07 mmol/L) males, &le;12 g/dL (7.45 mmol/L) females on at least one occasion occurred in 11% of quetiapine patients in all trials including open label extensions. For these patients, the mean maximum decrease in haemoglobin at any time was &ndash;</p><p>1.50 g/dL.</p><p>23.&nbsp; &nbsp;These reports often occurred in the setting of tachycardia, dizziness, orthostatic hypotension and/or underlying cardiac/respiratory disease.</p><p>24.&nbsp; &nbsp;Based on shifts from normal baseline to potentially clinically important value at any time post- baseline in all trials. Shifts in total T4, free T4, total T3 and free T3 are defined as &lt;0.8 x LLN (pmol/L) and shift in TSH is &gt; 5 mIU/L at any time.</p><p>25.&nbsp; &nbsp;Based upon the increased rate of vomiting in elderly patients (&ge;65 years of age).</p><p>26.&nbsp; &nbsp;Based on shift in neutrophils from &gt; =1.5 x 109L at baseline to &lt;0.5 x 109/L at any time during treatment and based on patients with severe neutropenia (&lt;0.5 x 109/L) and infection during all quetiapine clinical trials (see section 4.4).</p><p>27.&nbsp; &nbsp;Based on shifts from normal baseline to potentially clinically important value at any time post- baseline in all trials. Shifts in eosinophils are defined as &gt;1 x 109 cells/L at any time.</p><p>28.&nbsp; &nbsp;Based on shifts from normal baseline to potentially clinically important value at any time post- baseline in all trials. Shifts in WBCs are defined as &le;3 x 109 cells/L at any time.</p><p>29.&nbsp; &nbsp;Based on adverse event reports of metabolic syndrome from all clinical trials with quetiapine.</p><p>30.&nbsp; &nbsp;In some patients, a worsening of more than one of the metabolic factors of weight, blood glucose and lipids was observed in clinical studies (see section 4.4).</p><p>31.&nbsp; &nbsp;See section 4.6</p><p>32.&nbsp; &nbsp;May occur at or near initiation of treatment and be associated with hypotension and/or syncope. Frequency based on adverse event reports of bradycardia and related events in all</p><p>clinical trials with quetiapine.</p><p>33. Based on one retrospective non-randomised<br />epidemiological study.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Cases of QT prolongation, ventricular arrhythmia, sudden unexplained death, cardiac arrest and torsades de pointes have been reported with the use of neuroleptics and are considered class effects.</p><p>Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal<br />necrolysis (TEN), drug reaction with eosinophilia and<br />systemic symptoms (DRESS) have been reported in<br />association with quetiapine treatment.</p><p><u>Paediatric population</u></p><p>The same ADRs described above for adults should be considered for children and adolescents. The following table summarises ADRs that occur in a higher</p><p>frequency category in children and adolescent patients (10-17 &nbsp;years of age) than in the adult population or ADRs that have not been identified in the adult population.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADRs in children and adolescents associated with quetiapine therapy that occur in a higher frequency than adults, or not identified in the adult population</strong></p><p>&nbsp;</p><p>The frequencies of adverse events are ranked according to the following: Very common (&gt;1/10), common (&gt;1/100, &lt;1/10), uncommon (&gt;1/1000, &lt;1/100), rare (&gt;1/10,000, &lt;1/1000) and very rare (&lt;1/10,000).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>SOC</strong></p></td><td><p><strong>Very Common</strong></p></td><td><p><strong>Common</strong></p></td></tr><tr><td><p><em>Endocrine disorders</em></p></td><td><p>Elevations in prolactin1</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em>Metabolism and nutritional disorders</em></p></td><td><p>Increased appetite</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em>Nervous system disorders</em></p></td><td><p>Extrapyramidal symptoms3, 4</p></td><td><p>Syncope</p></td></tr><tr><td><p><em>Vascular disorders</em></p></td><td><p>Increases in blood pressure2</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td><p>&nbsp;</p></td><td><p>Rhinitis</p></td></tr><tr><td><p><em>Gastrointestinal disorders</em></p></td><td><p>Vomiting</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em>General disorders and administration site conditions</em></p></td><td><p>&nbsp;</p></td><td><p>Irritability3</p></td></tr></tbody></table><p>&nbsp;</p><p>1. &nbsp;Prolactin levels (patients &lt; 18 years of age): &gt;20 &mu;g/L (&gt;869.56 pmol/L) males; &gt;26 &mu;g/L (&gt;1130.428 pmol/L) females at any time. Less than 1% of patients had an increase to a prolactin level &gt;100 &mu;g/L.</p><p>2. &nbsp;Based on shifts above clinically significant thresholds (adapted from the National Institutes of Health criteria) or increases &gt;20 mmHg for systolic or &gt;10 mmHg for diastolic blood pressure at any time in two acute (3-6 weeks) placebo-controlled trials in children and adolescents.</p><p>3. &nbsp;Note: The frequency is consistent to that observed in adults, but might be associated with different clinical implications in children and adolescents as compared to adults.</p><p>4. &nbsp;See section 5.1.</p><p>&nbsp;</p><p>To report any side effects:</p><p>Saudi Arabia:</p><p>- The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp;SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>Other GCC states:</p><p>-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>S</u><u>y</u><u>mptoms</u></p><p>In general, reported signs and symptoms were those resulting from an exaggeration of the active substance&rsquo;s known pharmacological effects, i.e. drowsiness and sedation, tachycardia, hypotension and anti-cholinergic effects.</p><p>Overdose could lead to QT-prolongation, seizures, status epilepticus, rhabdomyolysis, respiratory depression, urinary retention, confusion, delirium and/or agitation, coma and death. Patients with pre-existing severe cardiovascular disease may be at an increased risk of the effects of overdose. (see section 4.4, Orthostatic hypotension).</p><p><u>Management of overdose</u></p><p>There is no specific antidote to quetiapine. In cases of severe signs, the possibility of multiple drug involvement should be considered, and intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system.</p><p>Based on public literature, patients with delirium and agitation and a clear anti- cholinergic syndrome may be treated with physostigmine, 1-2 mg (under continuous ECG monitoring). &nbsp;This is not recommended as standard treatment, because of potential negative effect of physostigmine on cardiac conductance. Physostigmine may be used if there are no ECG aberrations. Do not use&nbsp; physostigmine in case of dysrhythmias, any degree of heart block or QRS- widening.</p><p>Whilst the prevention of absorption in overdose has not been investigated, gastric lavage can be indicated in severe poisonings and if possible to perform within one hour of ingestion. The administration of activated charcoal should be considered.</p><p>&nbsp;</p><p>In cases of quetiapine overdose, refractory hypotension should be treated with appropriate measures such as intravenous fluids and/or sympathomimetic agents. Epinephrine and dopamine should be avoided, since beta stimulation may worsen hypotension in the setting of quetiapine-induced alpha blockade.</p><p>&nbsp;</p><p>Close medical supervision and monitoring should be continued until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antipsychotics, ATC code: N05A H04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Quetiapine is an atypical antipsychotic agent. Quetiapine and the active human plasma metabolite, norquetiapine interact with a broad range of neurotransmitter receptors. Quetiapine and norquetiapine exhibit affinity for brain serotonin (5HT2) and dopamine D1- and D2- receptors. It is this combination of receptor antagonism with a higher selectivity for 5HT2 relative to D2- receptors, which is believed to contribute to the clinical antipsychotic properties and low extrapyramidal side effect (EPS) liability of Seroquel compared to typical antipsychotics. Quetiapine</p><p>and norquetiapine have no appreciable affinity at benzodiazepine receptors but high affinity at histaminergic and adrenergic alpha1 receptors and moderate affinity at adrenergic alpha2 receptors. Quetiapine also has low or no affinity for muscarinic receptors, while norquetiapine has moderate to high affinity at several muscarinic receptors, which may explain anti-cholinergic (muscarinic) effects. Inhibition of NET and partial agonist action at 5HT1A sites by norquetiapine may contribute to Seroquel&rsquo;s therapeutic efficacy as an antidepressant.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Quetiapine is active in tests for antipsychotic activity, such as conditioned avoidance. It also blocks the action of dopamine agonists, measured either behaviourally or electrophysiologically, and elevates dopamine metabolite concentrations, a neurochemical index of D2-receptor blockade.</p><p>&nbsp;</p><p>In pre-clinical tests predictive of EPS, quetiapine is unlike typical antipsychotics and has an atypical profile. Quetiapine does not produce dopamine D2 receptor supersensitivity after chronic administration. Quetiapine produces only weak catalepsy at effective dopamine D2 receptor blocking doses. Quetiapine demonstrates selectivity for the limbic system by producing depolarisation</p><p>blockade of the mesolimbic but not the nigrostriatal dopamine-containing neurones following chronic administration. Quetiapine exhibits minimal dystonic liability in&nbsp;</p><p>&nbsp;</p><p>haloperidol-sensitised or drug-naive Cebus monkeys after acute and chronic administration (see section 4.8).</p><p>&nbsp;</p><p><u>Clinical efficacy:</u></p><p>&nbsp;</p><p><em>Schizophrenia</em></p><p>In three placebo-controlled clinical trials, in patients with schizophrenia, using variable doses of quetiapine, there were no differences between the Seroquel and placebo treatment groups in the incidence of EPS or concomitant use of anti- cholinergics. A placebo-controlled trial evaluating fixed doses of quetiapine across the range of 75 to 750 mg/day showed no evidence of an increase in EPS or the use of concomitant anti-cholinergics. The long-term efficacy of Seroquel IR in prevention of schizophrenic relapses has not been verified in blinded clinical trials. In open label trials, in patients with schizophrenia, quetiapine was effective in maintaining the clinical improvement during continuation therapy in patients who showed an initial treatment response, suggesting some long-term efficacy.</p><p>&nbsp;</p><p><em>Bipolar disorder</em></p><p>In four placebo-controlled clinical trials, evaluating doses of Seroquel up to</p><p>800 mg/day for the treatment of moderate to severe manic episodes, two each in monotherapy and as combination therapy to lithium or divalproex, , there were no differences between the Seroquel and placebo treatment groups in the incidence of EPS or concomitant use of anti-cholinergics.</p><p>&nbsp;</p><p>In the treatment of moderate to severe manic episodes, Seroquel demonstrated superior efficacy to placebo in reduction of manic symptoms at 3 and 12 weeks, in two monotherapy trials. There are no data from long-term studies to demonstrate Seroquel&rsquo;s effectiveness in preventing subsequent manic or depressive episodes. Seroquel data in combination with divalproex or lithium in acute moderate to severe manic episodes at 3 and 6 weeks is limited; however, combination therapy was well tolerated. The data showed an additive effect at week 3. A second study did not demonstrate an additive effect at week 6.</p><p>&nbsp;</p><p>The mean last week median dose of Seroquel in responders was approximately</p><p>600 mg/day and approximately 85% of the responders were in the dose range of</p><p>400 to 800 mg/day.</p><p>&nbsp;</p><p>In 4 clinical trials with a duration of 8 weeks in patients with moderate to severe depressive episodes in bipolar I or bipolar II disorder, Seroquel IR 300 mg and</p><p>600 mg was significantly superior to placebo treated patients for the relevant</p><p>outcome measures: mean improvement on the MADRS and for response defined as</p><p>at least a 50% improvement in MADRS total score from baseline. There was no difference in magnitude of effect between the patients who received 300 mg Seroquel IR and those who received 600 mg dose.</p><p>&nbsp;</p><p>In the continuation phase in two of these studies, it was demonstrated that long- term treatment, of patients who responded on Seroquel IR 300 or 600 mg, was efficacious compared to placebo treatment with respect to depressive symptoms, but not with regard to manic symptoms.</p><p>&nbsp;</p><p>In two recurrence prevention studies evaluating Seroquel in combination with mood stabilizers, in patients with manic, depressed or mixed mood episodes, the&nbsp;</p><p>combination with Seroquel was superior to mood stabilizers monotherapy in increasing the time to recurrence of any mood event (manic, mixed or depressed). Seroquel was administered twice-daily totalling 400 mg to 800 mg a day as combination therapy to lithium or valproate.</p><p>&nbsp;</p><p>In a 6-week, randomised, study of lithium and Seroquel XL versus placebo and Seroquel XL in adult patients with acute mania, the difference in YMRS mean improvement between the lithium add-on group and the placebo add-on group was</p><p>2.8 points and the difference in % responders (defined as 50% improvement from baseline on the YMRS) was 11% (79% in the lithium add-on group vs. 68% in the placebo add-on group).</p><p>&nbsp;</p><p>In one long-term study (up to 2 years treatment) evaluating recurrence prevention in patients with manic, depressed or mixed mood episodes quetiapine was superior to placebo in increasing the time to recurrence of any mood event (manic, mixed or depressed), in patients with bipolar I disorder. The number of patients with a mood event was 91 (22.5%) in the quetiapine group, 208 (51.5%) in the placebo group</p><p>and 95 (26.1%) in the lithium treatment groups respectively. In patients who responded to quetiapine, when comparing continued treatment with quetiapine to</p><p>switching to lithium, the results indicated that a switch to lithium treatment does</p><p>not appear to be associated with an increased time to recurrence of a mood event.</p><p>&nbsp;</p><p>Clinical trials have demonstrated that Seroquel is effective in schizophrenia and mania when given twice a day, although quetiapine has a pharmacokinetic half-life of approximately 7 hours. This is further supported by the data from a positron emission tomography (PET) study, which identified that for quetiapine, 5HT2- and D2-receptor occupancy are maintained for up to 12 hours. The safety and efficacy of doses greater than 800 mg/day have not been evaluated.</p><p>&nbsp;</p><p><u>Clinical safety</u></p><p>In short-term, placebo-controlled clinical trials in schizophrenia and bipolar mania the aggregated incidence of extrapyramidal symptoms was similar to placebo (schizophrenia: 7.8% for quetiapine and 8.0% for placebo; bipolar mania: 11.2% for quetiapine and 11.4% for placebo). Higher rates of extrapyramidal symptoms were seen in quetiapine treated patients compared to those treated with placebo in short-term, placebo-controlled clinical trials in MDD and bipolar depression. In</p><p>short-term, placebo-controlled bipolar depression trials the aggregated incidence of extrapyramidal symptoms was 8.9% for quetiapine compared to 3.8% for placebo. In short-term, placebo-controlled monotherapy clinical trials in major depressive disorder the aggregated incidence of extrapyramidal symptoms was 5.4% for</p><p>Seroquel XL and 3.2% for placebo. In a short-term placebo-controlled monotherapy trial in elderly patients with major depressive disorder, the aggregated incidence of extrapyramidal symptoms was 9.0% for Seroquel XL and 2.3% for placebo. In both bipolar depression and MDD, the incidence of the individual adverse events (eg, akathisia, extrapyramidal disorder, tremor, dyskinesia, dystonia, restlessness,</p><p>muscle contractions involuntary, psychomotor hyperactivity and muscle rigidity)</p><p>did not exceed 4% in any treatment group.</p><p>&nbsp;</p><p>In short-term, fixed-dose (50mg/d to 800 mg/d), placebo-controlled studies</p><p>(ranging from 3 to 8 weeks), the mean weight gain for quetiapine-treated patients</p><p>&nbsp;</p><p>&nbsp;</p><p>ranged from 0.8 kg for the 50 mg daily dose to 1.4 kg for the 600 mg daily dose (with lower gain for the 800 mg daily dose), compared to 0.2 kg for the placebo treated patients.&nbsp; The percentage of quetiapine treated patients who gained &ge;7% of body weight ranged from 5.3% for the 50 mg daily dose to 15.5% for the 400 mg daily dose (with lower gain for the 600 and 800 mg daily doses), compared to 3.7% for placebo treated patients.</p><p>&nbsp;</p><p>A 6-week, randomised, study of lithium and Seroquel XL versus placebo and Seroquel XL in adult patients with acute mania indicated that the combination of Seroquel XL with lithium leads to more adverse events (63% versus 48% in Seroquel XL in combination with placebo). The safety results showed a higher incidence of extrapyramidal symptoms reported in 16.8% of patients in the lithium add-on group and 6.6% in the placebo add-on group, the majority of which consisted of tremor, reported in 15.6% of the patients in the lithium add-on group and 4.9% in the placebo add-on group. The incidence of somnolence was higher in the Seroquel XL with lithium add-on group (12.7%) compared to the Seroquel XL with the placebo add-on group (5.5%). In addition, a higher percentage of patients treated in the lithium add-on group (8.0%) had weight gain (&ge;7%) at the end of treatment compared to patients in the placebo add-on group (4.7%).</p><p>&nbsp;</p><p>Longer term relapse prevention trials had an open label period (ranging from 4 to</p><p>36 weeks) during which patients were treated with quetiapine, followed by a randomized withdrawal period during which patients were randomized to quetiapine or placebo. For patients who were randomized to quetiapine, the mean weight gain during the open label period was 2.56 kg, and by week 48 of the randomized period, the mean weight gain was 3.22 kg, compared to open label baseline. For patients who were randomized to placebo, the mean weight gain</p><p>during the open label period was 2.39 kg, and by week 48 of the randomized period the mean weight gain was 0.89 kg, compared to open label baseline.</p><p>&nbsp;</p><p>In placebo-controlled studies in elderly patients with dementia-related psychosis, the incidence of cerebrovascular adverse events per 100 patient years was not higher in quetiapine-treated patients than in placebo-treated patients.</p><p>&nbsp;</p><p>In all short-term placebo-controlled monotherapy trials in patients with a baseline neutrophil count &ge;1.5 x 109/L, the incidence of at least one occurrence of a shift to neutrophil count &lt;1.5 x 109/L, was 1.9% in patients treated with quetiapine compared to 1.5% in placebo-treated patients. The incidence of shifts to &gt;0.5-&lt;1.0 x 109/L was the same (0.2%) in patients treated with quetiapine as with placebo- treated patients. In all clinical trials (placebo-controlled, open-label, active</p><p>comparator) in patients with a baseline neutrophil count &ge;1.5 x 109/L, the incidence of at least one occurrence of a shift to neutrophil count &lt;1.5 x 109/L was 2.9% and to &lt;0.5 x 109/L was 0.21% in patients treated with quetiapine.</p><p>&nbsp;</p><p>Quetiapine treatment was associated with dose-related decreases in thyroid hormone levels.&nbsp; The incidences of shifts in TSH was 3.2% for quetiapine versus</p><p>2.7% for placebo. The incidence of reciprocal, potentially clinically significant shifts of both T3 or T4 and TSH in these trials were rare, and the observed changes</p><p>&nbsp;</p><p>in thyroid hormone levels were not associated with clinically symptomatic hypothyroidism.</p><p>&nbsp;</p><p>The reduction in total and free T4 was maximal within the first six weeks of quetiapine treatment, with no further reduction during long-term treatment. For about 2/3 of all cases, cessation of quetiapine treatment was associated with a reversal of the effects on total and free T4, irrespective of the duration of treatment.</p><p>&nbsp;</p><p><em>Cataracts/lens opacities</em></p><p>In a clinical trial to evaluate the cataractogenic potential of Seroquel (200-</p><p>800 mg/day) versus risperidone (2-8 mg/day) in patients with schizophrenia or schizoaffective disorder, the percentage of patients with increased lens opacity grade was not higher in Seroquel (4%) compared with risperidone (10%), for patients with at least 21 months of exposure.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><u>Clinical efficacy</u></p><p>The efficacy and safety of Seroquel was studied in a 3-week placebo controlled study for the treatment of mania (n= 284 patients from the US, aged 10-17). About</p><p>45% of the patient population had an additional diagnosis of ADHD. In addition, a</p><p>6-week placebo controlled study for the treatment of schizophrenia (n = 222 patients, aged 13-17) was performed. In both studies, patients with known lack of response to Seroquel were excluded. Treatment with Seroquel was initiated at</p><p>50 mg/day and on day 2 increased to 100 mg/day; subsequently the dose was titrated to a target dose (mania 400-600 mg/day; schizophrenia 400-800 mg/day) using increments of 100 mg/day given two or three times daily.</p><p>&nbsp;</p><p>In the mania study, the difference in LS mean change from baseline in YMRS total score (active minus placebo) was &ndash;5.21 for Seroquel 400 mg/day and &ndash;6.56 for Seroquel 600 mg/day. Responder rates (YMRS improvement &ge;50%) were 64% for Seroquel 400 mg/day, 58% for 600 mg/day and 37% in the placebo arm.</p><p>&nbsp;</p><p>In the schizophrenia study, the difference in LS mean change from baseline in</p><p>PANSS total score (active minus placebo) was &ndash;8.16 for Seroquel 400 mg/day and</p><p>&ndash;9.29 for Seroquel 800 mg/day. Neither low dose (400 mg/day) nor high dose regimen (800 mg/day) quetiapine was superior to placebo with respect to the percentage of patients achieving response, defined as &ge;30% reduction from baseline in PANSS total score. Both in mania and schizophrenia higher doses resulted in numerically lower response rates.</p><p>&nbsp;</p><p>In a third short-term placebo-controlled monotherapy trial with Seroquel XL in children and adolescent patients (10-17 years of age) with bipolar depression, efficacy was not demonstrated.</p><p>&nbsp;</p><p>No data are available on maintenance of effect or recurrence prevention in this age group.</p><p>&nbsp;</p><p><u>Clinical safety</u></p><p>In the short-term paediatric trials with quetiapine described above, the rates of EPS in the active arm vs. placebo were 12.9% vs. 5.3% in the schizophrenia trial, 3.6% vs. 1.1% in the bipolar mania trial, and 1.1% vs. 0% in the bipolar depression trial. The rates of weight gain &ge; 7% of baseline body weight in the active arm vs. placebo were 17% vs. 2.5% in the schizophrenia and bipolar mania trials, and 13.7% vs.</p><p>6.8% in the bipolar depression trial. The rates of suicide related events in the active arm vs. placebo were 1.4% vs. 1.3% in the schizophrenia trial, 1.0% vs. 0% in the bipolar mania trial, and 1.1% vs. 0% in the bipolar depression trial. During an extended post treatment follow-up phase of the bipolar depression trial, there were two additional suicide related events in two patients; one of these patients was on quetiapine at the time of the event.</p><p>&nbsp;</p><p><u>Long-term safety</u></p><p>A 26-week open-label extension to the acute trials (n=380 patients), with Seroquel flexibly dosed at 400- 800 mg/day, provided additional safety data. Increases in blood pressure were reported in children and adolescents and increased appetite, extrapyramidal symptoms and elevations in serum prolactin were reported with higher frequency in children and adolescents than in adult patients (see sections 4.4 and 4.8). With respect to weight gain, when adjusting for normal growth over the longer term, an increase of at least 0.5 standard deviation from baseline in Body Mass Index (BMI) was used as a measure of a clinically significant change; 18.3% of patients who were treated with quetiapine for at least 26 weeks met this criterion.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Quetiapine is well absorbed and extensively metabolised following oral administration. The bioavailability of quetiapine is not significantly affected by administration with food. Steady-state peak molar concentrations of the active metabolite norquetiapine are 35% of that observed for quetiapine.</p><p>&nbsp;</p><p>The pharmacokinetics of quetiapine and norquetiapine are linear across the approved dosing range.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Quetiapine is approximately 83% bound to plasma proteins.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Quetiapine is extensively metabolised by the liver, with parent compound accounting for less than 5% of unchanged drug-related material in the urine or faeces, following the administration of radiolabelled quetiapine. <em>In vitro </em>investigations established that CYP3A4 is the primary enzyme responsible for cytochrome P450 mediated metabolism of quetiapine. Norquetiapine is primarily formed and eliminated via CYP3A4.</p><p>&nbsp;</p><p>Approximately 73% of the radioactivity is excreted in the urine and 21% in the faeces.</p><p>Quetiapine and several of its metabolites (including norquetiapine) were found to be weak inhibitors of human cytochrome P450 1A2, 2C9, 2C19, 2D6 and 3A4 activities in vitro. In vitro CYP inhibition is observed only at concentrations approximately 5 to 50 fold higher than those observed at a dose range of 300 to</p><p>800 mg/day in humans. Based on these <em>in vitro </em>results, it is unlikely that co-</p><p>administration of quetiapine with other drugs will result in clinically significant drug inhibition of cytochrome P450 mediated metabolism of the other drug. From animal studies it appears that quetiapine can induce cytochrome P450 enzymes. In a specific interaction study in psychotic patients, however, no increase in the cytochrome P450 activity was found after administration of quetiapine.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The elimination half lives of quetiapine and norquetiapine are approximately 7 and</p><p>12 hours, respectively. The average molar dose fraction of free quetiapine and the</p><p>active human plasma metabolite norquetiapine is &lt;5% excreted in the urine.</p><p>&nbsp;</p><p><em>Special populations</em></p><p>&nbsp;</p><p><u>Gender</u></p><p>The kinetics of quetiapine do not differ between men and women.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>The mean clearance of quetiapine in the elderly is approximately 30 to 50% lower than that seen in adults aged 18 to 65 years.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>The mean plasma clearance of quetiapine was reduced by approximately 25% in subjects with severe renal impairment (creatinine clearance less than</p><p>30 ml/min/1.73m2), but the individual clearance values are within the range for</p><p>normal subjects.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>The mean quetiapine plasma clearance decreases with approx. 25% in persons with</p><p>known hepatic impairment (stable alcohol cirrhosis). As quetiapine is extensively metabolised by the liver, elevated plasma levels are expected in the population with hepatic impairment. Dose adjustments may be necessary in these patients (see</p><p>section 4.2).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Pharmacokinetic data were sampled in 9 children aged 10-12 years old and 12 adolescents, who were on steady-state treatment with 400 mg quetiapine twice daily. At steady-state, the dose-normalised plasma levels of the parent compound, quetiapine, in children and adolescents (10-17 years of age) were in general similar to adults, though Cmax in children was at the higher end of the range observed in adults. The AUC and Cmax for the active metabolite, norquetiapine, were higher, approximately 62% and 49% in children (10-12 years), respectively and 28% and</p><p>14% in adolescents (13-17 years), respectively, compared to adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There was no evidence of genotoxicity in a series of <em>in vitro </em>and <em>in vivo </em>genotoxicity studies. In laboratory animals at a clinically relevant exposure level the following deviations were seen, which as yet have not been confirmed in long- term clinical research:</p><p>&nbsp;</p><p>In rats, pigment deposition in the thyroid gland has been observed; in cynomolgus monkeys thyroid follicular cell hypertrophy, a lowering in plasma T3 levels, decreased haemoglobin concentration and a decrease of red and white blood cell count have been observed; and in dogs lens opacity and cataracts. (For cataracts/lens opacities, see section 5.1).</p><p>&nbsp;</p><p>In an embryofetal toxicity study in rabbits the foetal incidence of carpal/tarsal flexure was increased. This effect occurred in the presence of overt maternal effects such as reduced body weight gain. These effects were apparent at maternal</p><p>exposure levels similar or slightly above those in humans at the maximal therapeutic dose. The relevance of this finding for humans is unknown.</p><p>&nbsp;</p><p>In a fertility study in rats, marginal reduction in male fertility and pseudopregnancy, protracted periods of diestrus, increased precoital interval and reduced pregnancy rate were seen. These effects are related to elevated prolactin levels and not directly relevant to humans because of species differences in hormonal control of reproduction</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Core</u></p><p>Povidone</p><p>Calcium Hydrogen Phosphate Dihydrate</p><p>Microcrystalline Cellulose</p><p>Sodium Starch Glycolate Type A</p><p>Lactose Monohydrate</p><p>Magnesium Stearate</p><p>&nbsp;</p><p><u>Coating</u></p><p>Hypromellose 2910</p><p>Macrogol 400</p><p>Titanium Dioxide (E171)</p><p>Ferric Oxide, Yellow (E172) (25 mg and 100 mg tablets)</p><p>Ferric Oxide, Red (E172) (25 mg tablets)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/aluminium blisters</p><p>&nbsp;</p><p><u>Pack sizes</u></p><p>&nbsp;</p><p>Blisters:</p><p>&nbsp;</p><p><strong><em>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Tablet Strength&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carton (pack)</em></strong></p><p><strong><em>c</em></strong><strong><em>ontents</em></strong></p><p>&nbsp;</p><p><strong><em>Blisters</em></strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>25 mg tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</em></strong></p><p><strong><em>&nbsp; </em></strong><em>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 1 blister of 6 tablets<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;20 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2 blisters of 10 tablets<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 30 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 3 blisters of 10 tablets<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 50 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;10 blisters of 5 tablets</em></p><p><em>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;5 blisters of 10 tablets<br /><br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;60 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;&nbsp;6 blisters of 10 tablets<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 12 blisters of 5 tablets<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 100 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;10 blisters of 10 tablets</em></p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>100 mg, and 200 mg tablets and 300 mg tablets</em></strong></p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;10 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;1 blister of 10 tablets<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;20 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2 blisters of 10 tablets<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;30 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 3 blisters of 10 tablets<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;50 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;10 blisters of 5 tablets</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;5 blisters of 10 tablets<br /><br /><br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 60 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6 blisters of 10 tablets<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 90 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;9 blisters of 10 tablets<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;100 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 10 blisters of 10 tablets<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 120 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 12 blisters of 10 tablets (300 mg tablets only)<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 180 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;18 blisters of 10 tablets (300 mg tablets only)<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;240 tablets&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;24 blisters of 10 tablets (300 mg tablets only)</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Luye Pharma Limited
Surrey Technology Centre, 40 Occam Road
Surrey Research Park
Guilford
GU2 7YG
United Kingdom.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22th September 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>